var title_f11_46_12000="MDI use with trach";
var content_f11_46_12000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Equipment for aerosol delivery to tracheostomy in spontaneously breathing patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12000=[""].join("\n");
var outline_f11_46_12000=null;
var title_f11_46_12001="Hashimotos thyroiditis FNA I";
var content_f11_46_12001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hashimoto's thyroiditis: Findings on fine needle aspirate of the thyroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of the thyroid in Hashimoto's thyroiditis. Lymphocytes are predominant, sometimes surrounding rare follicular cells. No formed follicles are seen. Some colloid is present in the background.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12001=[""].join("\n");
var outline_f11_46_12001=null;
var title_f11_46_12002="Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)";
var content_f11_46_12002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/59/41906\">",
"         Patient information: Nutrition before and during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/13/32979\">",
"         Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gestational-diabetes-diabetes-that-starts-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H469648842\">",
"      <span class=\"h1\">",
"       What is gestational diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gestational diabetes, like &ldquo;regular&rdquo; diabetes, is a disorder that disrupts the way your body uses sugar.",
"     </p>",
"     <p>",
"      All the cells in your body need sugar to work normally. Sugar gets into the cells with the help of a hormone called insulin. If there is not enough insulin, or if the body stops responding to insulin, sugar builds up in the blood. That is what happens to people with diabetes.",
"     </p>",
"     <p>",
"      Gestational diabetes is a form of diabetes that affects some women when they are pregnant. It happens because pregnancy increases the body&rsquo;s need for insulin, but the body cannot always make enough.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648849\">",
"      <span class=\"h1\">",
"       What does gestational diabetes do to a woman and her baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can make the baby get too big (heavier than 9 pounds). That is a problem, because a big baby can get hurt if it cannot fit easily through the vagina. A big baby can also damage his or her mother&rsquo;s body during delivery. Sometimes, the baby will not fit and the mother has to have a c-section (surgery to get the baby out).",
"     </p>",
"     <p>",
"      Gestational diabetes also increases the risk that a woman will have a life-threatening problem during pregnancy called preeclampsia. (Preeclampsia causes high blood pressure, among other things.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648856\">",
"      <span class=\"h1\">",
"       Will I get gestational diabetes during my pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is hard to predict which women will get gestational diabetes. But some women are more likely to get it than others. You are more likely to get gestational diabetes if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Had it before",
"       </li>",
"       <li>",
"        Are overweight",
"       </li>",
"       <li>",
"        Have diabetes in your family",
"       </li>",
"       <li>",
"        Are older than 25",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648863\">",
"      <span class=\"h1\">",
"       Will I be tested for gestational diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. All pregnant women are tested for gestational diabetes.",
"     </p>",
"     <p>",
"      Most women should be tested when they are about 6 or 7 months pregnant. (That&rsquo;s the same as 24 to 28 weeks pregnant.) But women at high risk for diabetes may need to be tested earlier in pregnancy.",
"     </p>",
"     <p>",
"      There are a few ways to test for diabetes. A common way is to have you drink a special, sweet drink. Then, an hour or more later, your doctor or nurse will take some blood. That way he or she can see how high your blood sugar gets after you eat sugar.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648870\">",
"      <span class=\"h1\">",
"       How is gestational diabetes treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To treat your gestational diabetes, you will need to check your blood sugar often. This is something you can learn how to do on your own with an easy-to-use machine. Most women can control their blood sugar level by changing their diet. Some women also need insulin shots or other diabetes medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648877\">",
"      <span class=\"h1\">",
"       How should I change my diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A registered dietitian can tell you how to change your diet. Each woman is a little different, so there is no single diet that is right for everyone. Even so, most women should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid sweets and fatty foods",
"       </li>",
"       <li>",
"        Choose bread and rice made with whole grains",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648884\">",
"      <span class=\"h1\">",
"       Should I exercise?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You do not need to exercise to treat gestational diabetes. But being active will help control your blood sugar. If you already exercise, keep doing what you have been doing. If you have not been exercising and want to start, ask your doctor or nurse what kind of activity is safe for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648891\">",
"      <span class=\"h1\">",
"       How often do I need to see the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with gestational diabetes need to see the doctor or nurse more often than other pregnant women. How often you go will depend on how you are doing at each visit, and on whether you use insulin. During these visits, the doctor or nurse will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check on your baby",
"       </li>",
"       <li>",
"        Ask about your diet",
"       </li>",
"       <li>",
"        Make sure your blood sugar levels are where they should be",
"       </li>",
"       <li>",
"        Adjust your dose of insulin (if you use insulin)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648898\">",
"      <span class=\"h1\">",
"       Can I have a normal delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your blood sugar levels have been close to normal, chances are good that you will have a normal delivery. During delivery, your doctor or nurse will keep checking your blood sugar to make sure that it does not get too high.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648905\">",
"      <span class=\"h1\">",
"       What happens after I give birth?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your diabetes will probably go away and your blood sugar will probably go back to normal. If you were taking insulin, you probably will not need it anymore. Even so, your doctor or nurse should check your blood sugar to make sure your levels get back to normal and stay that way. Women who have gestational diabetes are at very high risk of getting &ldquo;regular&rdquo; diabetes later in life. You should get checked for diabetes every few years for the rest of your life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H469648912\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41906?source=see_link\">",
"       Patient information: Nutrition before and during pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"       Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/46/12002?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15435 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12002=[""].join("\n");
var outline_f11_46_12002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648842\">",
"      What is gestational diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648849\">",
"      What does gestational diabetes do to a woman and her baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648856\">",
"      Will I get gestational diabetes during my pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648863\">",
"      Will I be tested for gestational diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648870\">",
"      How is gestational diabetes treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648877\">",
"      How should I change my diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648884\">",
"      Should I exercise?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648891\">",
"      How often do I need to see the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648898\">",
"      Can I have a normal delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648905\">",
"      What happens after I give birth?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469648912\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=related_link\">",
"      Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41906?source=related_link\">",
"      Patient information: Nutrition before and during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_46_12003="Calculator: WHO Infant Weight for Age Percentiles (< 24 months)";
var content_f11_46_12003=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"WHOInfantWeightForAge_form\" name=\"WHOInfantWeightForAge_form\" onkeydown=\"clrResults();\" onkeyup=\"WHOInfantWeightForAge_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: WHO Infant Weight for Age Percentiles (&lt; 24 months)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sex",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input checked=\"checked\" name=\"Sex_radio\" onclick=\"WHOInfantWeightForAge_fx();\" type=\"radio\" value=\"Female\"/>",
"             Female",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\">",
"            <br/>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input name=\"Sex_radio\" onclick=\"WHOInfantWeightForAge_fx();\" type=\"radio\" value=\"Male\"/>",
"             Male",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"WHOInfantWeightForAge_fx(); minMaxCheck();\" onchange=\"WHOInfantWeightForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"WHOInfantWeightForAge_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mo\">",
"              mo",
"             </option>",
"             <option value=\"12|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"WHOInfantWeightForAge_fx(); minMaxCheck();\" onchange=\"WHOInfantWeightForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"WHOInfantWeightForAge_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Z Score",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Percentile",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"WHOInfantWeightForAge_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option selected=\"selected\">",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Weight percentiles are best interpreted with reference to height (see calculator for Infant weight for length percentiles.)",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Girls: Weight-for-age. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Boys: Weight-for-age. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12003=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.WHOInfantWeightForAge_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function WHOInfantWeightForAge_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.WHOInfantWeightForAge_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"if (Sex == 1){",
"if(Age >= 0 && Age < 1){L = 0.3809; M = 3.2322; S = 0.14171;};",
"if(Age >= 1 && Age < 2){L = 0.1714; M = 4.1873; S = 0.13724;};",
"if(Age >= 2 && Age < 3){L = 0.0962; M = 5.1282; S = 0.13000;};",
"if(Age >= 3 && Age < 4){L = 0.0402; M = 5.8458; S = 0.12619;};",
"if(Age >= 4 && Age < 5){L = -0.0050; M = 6.4237; S = 0.12402;};",
"if(Age >= 5 && Age < 6){L = -0.0430; M = 6.8985; S = 0.12274;};",
"if(Age >= 6 && Age < 7){L = -0.0756; M = 7.2970; S = 0.12204;};",
"if(Age >= 7 && Age < 8){L = -0.1039; M = 7.6422; S = 0.12178;};",
"if(Age >= 8 && Age < 9){L = -0.1288; M = 7.9487; S = 0.12181;};",
"if(Age >= 9 && Age < 10){L = -0.1507; M = 8.2254; S = 0.12199;};",
"if(Age >= 10 && Age < 11){L = -0.1700; M = 8.4800; S = 0.12223;};",
"if(Age >= 11 && Age < 12){L = -0.1872; M = 8.7192; S = 0.12247;};",
"if(Age >= 12 && Age < 13){L = -0.2024; M = 8.9481; S = 0.12268;};",
"if(Age >= 13 && Age < 14){L = -0.2158; M = 9.1699; S = 0.12283;};",
"if(Age >= 14 && Age < 15){L = -0.2278; M = 9.3870; S = 0.12294;};",
"if(Age >= 15 && Age < 16){L = -0.2384; M = 9.6008; S = 0.12299;};",
"if(Age >= 16 && Age < 17){L = -0.2478; M = 9.8124; S = 0.12303;};",
"if(Age >= 17 && Age < 18){L = -0.2562; M = 10.0226; S = 0.12306;};",
"if(Age >= 18 && Age < 19){L = -0.2637; M = 10.2315; S = 0.12309;};",
"if(Age >= 19 && Age < 20){L = -0.2703; M = 10.4393; S = 0.12315;};",
"if(Age >= 20 && Age < 21){L = -0.2762; M = 10.6464; S = 0.12323;};",
"if(Age >= 21 && Age < 22){L = -0.2815; M = 10.8534; S = 0.12335;};",
"if(Age >= 22 && Age < 23){L = -0.2862; M = 11.0608; S = 0.12350;};",
"if(Age >= 23 && Age < 24){L = -0.2903; M = 11.2688; S = 0.12369;};",
"if(Age >= 24 && Age < 25){L = -0.2941; M = 11.4775; S = 0.12390;};",
"}",
"if (Sex == 2){",
"if(Age >= 0 && Age < 1){L = 0.3487; M = 3.3464; S = 0.14602;};",
"if(Age >= 1 && Age < 2){L = 0.2297; M = 4.4709; S = 0.13395;};",
"if(Age >= 2 && Age < 3){L = 0.1970; M = 5.5675; S = 0.12385;};",
"if(Age >= 3 && Age < 4){L = 0.1738; M = 6.3762; S = 0.11727;};",
"if(Age >= 4 && Age < 5){L = 0.1553; M = 7.0023; S = 0.11316;};",
"if(Age >= 5 && Age < 6){L = 0.1395; M = 7.5105; S = 0.11080;};",
"if(Age >= 6 && Age < 7){L = 0.1257; M = 7.9340; S = 0.10958;};",
"if(Age >= 7 && Age < 8){L = 0.1134; M = 8.2970; S = 0.10902;};",
"if(Age >= 8 && Age < 9){L = 0.1021; M = 8.6151; S = 0.10882;};",
"if(Age >= 9 && Age < 10){L = 0.0917; M = 8.9014; S = 0.10881;};",
"if(Age >= 10 && Age < 11){L = 0.0820; M = 9.1649; S = 0.10891;};",
"if(Age >= 11 && Age < 12){L = 0.0730; M = 9.4122; S = 0.10906;};",
"if(Age >= 12 && Age < 13){L = 0.0644; M = 9.6479; S = 0.10925;};",
"if(Age >= 13 && Age < 14){L = 0.0563; M = 9.8749; S = 0.10949;};",
"if(Age >= 14 && Age < 15){L = 0.0487; M = 10.0953; S = 0.10976;};",
"if(Age >= 15 && Age < 16){L = 0.0413; M = 10.3108; S = 0.11007;};",
"if(Age >= 16 && Age < 17){L = 0.0343; M = 10.5228; S = 0.11041;};",
"if(Age >= 17 && Age < 18){L = 0.0275; M = 10.7319; S = 0.11079;};",
"if(Age >= 18 && Age < 19){L = 0.0211; M = 10.9385; S = 0.11119;};",
"if(Age >= 19 && Age < 20){L = 0.0148; M = 11.1430; S = 0.11164;};",
"if(Age >= 20 && Age < 21){L = 0.0087; M = 11.3462; S = 0.11211;};",
"if(Age >= 21 && Age < 22){L = 0.0029; M = 11.5486; S = 0.11261;};",
"if(Age >= 22 && Age < 23){L = -0.0028; M = 11.7504; S = 0.11314;};",
"if(Age >= 23 && Age < 24){L = -0.0083; M = 11.9514; S = 0.11369;};",
"if(Age >= 24 && Age < 25){L = -0.0137; M = 12.1515; S = 0.11426;};",
"}",
"Z_Score =  (power((Weight / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantWeightForAge_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 23.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 23.99 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight < 0.5) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 0.5 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 100) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 100 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantWeightForAge_form){",
"",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f11_46_12003=null;
var title_f11_46_12004="Polyclonal pattern on SPEP";
var content_f11_46_12004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74708%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74708%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polyclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Densitometer tracing of these findings reveals a broad-based peak of gamma mobility. This pattern is most often due to the presence of an inflammatory or reactive process, such as chronic liver disease, connective tissue disease, chronic infection, or a lymphoproliferative disorder.",
"    <br>",
"     (B) A polyclonal pattern is seen on serum protein electrophoresis on agarose gel (anode on left). The band at the right (red asterisk) is broad, and extends throughout the gamma mobility area.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Normal pattern on serum protein electrophoresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Looking from left to right on the serum protein electrophoresis, a normal pattern has a large peak representing albumin followed by significantly smaller peaks for alfa-1, alfa-2, beta, and gamma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12004=[""].join("\n");
var outline_f11_46_12004=null;
var title_f11_46_12005="Budding yeast";
var content_f11_46_12005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Budding yeast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Budding yeast representing C. glabrata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12005=[""].join("\n");
var outline_f11_46_12005=null;
var title_f11_46_12006="Dimenhydrinate: Drug information";
var content_f11_46_12006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimenhydrinate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/50/34596?source=see_link\">",
"    see \"Dimenhydrinate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/15/11509?source=see_link\">",
"    see \"Dimenhydrinate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dramamine&reg;  for kids [OTC];",
"     </li>",
"     <li>",
"      Dramamine&reg; [OTC];",
"     </li>",
"     <li>",
"      Driminate [OTC];",
"     </li>",
"     <li>",
"      TripTone&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dimenhydrinate&reg; [OTC];",
"     </li>",
"     <li>",
"      Children&rsquo;s Motion Sickness Liquid [OTC];",
"     </li>",
"     <li>",
"      Dimenhydrinate Injection;",
"     </li>",
"     <li>",
"      Dinate&reg; [OTC];",
"     </li>",
"     <li>",
"      Gravol IM;",
"     </li>",
"     <li>",
"      Gravol&reg; [OTC];",
"     </li>",
"     <li>",
"      Jamp-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Nauseatol [OTC];",
"     </li>",
"     <li>",
"      Novo-Dimenate [OTC];",
"     </li>",
"     <li>",
"      PMS-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Sandoz-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Travel Tabs [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Motion sickness (prevention/treatment):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 50-100 mg every 4-6 hours, not to exceed 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 50 mg every 4 hours; maximum: 100 mg every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F160767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/15/11509?source=see_link\">",
"      see \"Dimenhydrinate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Motion sickness (prevention/treatment):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-5 years: 12.5-25 mg every 6-8 hours, maximum: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 25-50 mg every 6-8 hours, maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 1.25 mg/kg",
"     <b>",
"      or",
"     </b>",
"     37.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     4 times/day; maximum: 300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (1 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dramamine&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Driminate: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TripTone&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dramamine&reg;: 50 mg [scored; contains phenylalanine 0.84 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dramamine&reg;  for kids: 25 mg [scored; dye free; contains phenylalanine 0.84 mg/tablet; grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7694532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: To prevent motion sickness, administer 30-60 minutes prior to exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Administer undiluted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Dilute and inject over 2 minutes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of nausea, vertigo, and vomiting associated with motion sickness",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14446198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nausea and vomiting of pregnancy (NVP)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DimenhyDRINATE may be confused with diphenhydrAMINE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, excitation, headache, insomnia, lassitude, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, epigastric distress, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Thickening of bronchial secretions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dimenhydrinate or any component of the formulation; neonates (injection contains benzyl alcohol)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibiotics: Use caution if used in conjunction with antibiotics that have the potential to cause ototoxicity. Dimenhydrinate may mask symptoms of ototoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium, etc) due to its potent anticholinergic effects  (Beers Criteria). Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in premature children and infants born with a low birth weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral formulations: Do not inject intra-arterially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F160746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14446199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. The risk of fetal abnormalities was not increased following maternal use of dimenhydrinate during any trimester of pregnancy. Dimenhydrinate is recommended for the treatment of nausea and vomiting of pregnancy. Dimenhydrinate may have an oxytocic effect if used during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7694529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14446200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of dimenhydrinate are excreted into breast milk. Irritability in a breast-feeding infant was noted in one study. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F160741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be taken with food or water. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dramamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (8): $2.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DimenhyDRINATE Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $7.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DimenhyDRINATE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $0.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dramamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (12): $3.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Triptone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (15): $2.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agolene (BE);",
"     </li>",
"     <li>",
"      Amosyt (SE);",
"     </li>",
"     <li>",
"      Anautin (DK, EC);",
"     </li>",
"     <li>",
"      Antemin (CH);",
"     </li>",
"     <li>",
"      Antivomit (FI);",
"     </li>",
"     <li>",
"      Aviomarin (PL);",
"     </li>",
"     <li>",
"      Biodramina (ES);",
"     </li>",
"     <li>",
"      Cinfamar (ES);",
"     </li>",
"     <li>",
"      Contramareo (ES);",
"     </li>",
"     <li>",
"      Daedalon (HU);",
"     </li>",
"     <li>",
"      Dekatravel (BE);",
"     </li>",
"     <li>",
"      Denim (TH);",
"     </li>",
"     <li>",
"      Devom (PK);",
"     </li>",
"     <li>",
"      Dimenate (HK, MY);",
"     </li>",
"     <li>",
"      Dimenhidrinato (MX);",
"     </li>",
"     <li>",
"      Dimenidrinato (IT);",
"     </li>",
"     <li>",
"      Dimicaps (MX);",
"     </li>",
"     <li>",
"      Divonal (PE);",
"     </li>",
"     <li>",
"      Doang (TW);",
"     </li>",
"     <li>",
"      Dramamine (AR, AU, BB, BD, BE, BF, BJ, BM, BS, BZ, CI, CL, CO, ET, GB, GH, GM, GN, GY, ID, IE, IN, JM, JP, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NL, NZ, PR, SC, SD, SG, SL, SN, SR, TN, TT, TW, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dramavir (ES);",
"     </li>",
"     <li>",
"      Dramavol (GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Dramin (BR);",
"     </li>",
"     <li>",
"      Dramina (HR);",
"     </li>",
"     <li>",
"      Driminate Supp (MY);",
"     </li>",
"     <li>",
"      Dromyl (NO);",
"     </li>",
"     <li>",
"      Garcol (HK);",
"     </li>",
"     <li>",
"      Gravamin (PE);",
"     </li>",
"     <li>",
"      Gravol (CR, DO, GT, HK, HN, IN, NI, PA, PE, PH, SV, TH);",
"     </li>",
"     <li>",
"      Hydrinate (MY);",
"     </li>",
"     <li>",
"      Lomarin (IT);",
"     </li>",
"     <li>",
"      Mareol (CO);",
"     </li>",
"     <li>",
"      Mareosan (ES);",
"     </li>",
"     <li>",
"      Marolin (ES);",
"     </li>",
"     <li>",
"      Menito (TW);",
"     </li>",
"     <li>",
"      Motivan (TH);",
"     </li>",
"     <li>",
"      Motozina (IT);",
"     </li>",
"     <li>",
"      Nausicalm (FR);",
"     </li>",
"     <li>",
"      Navamin (TH);",
"     </li>",
"     <li>",
"      Novomin (HK, MY);",
"     </li>",
"     <li>",
"      Paranausine (BE, LU);",
"     </li>",
"     <li>",
"      Pasedol (CO);",
"     </li>",
"     <li>",
"      RubieMen (DE);",
"     </li>",
"     <li>",
"      Travamin (IL);",
"     </li>",
"     <li>",
"      Travel Well (ES);",
"     </li>",
"     <li>",
"      Travel-Gum (CZ, IT);",
"     </li>",
"     <li>",
"      Trawell (CH);",
"     </li>",
"     <li>",
"      Trimin (TW);",
"     </li>",
"     <li>",
"      Vagomine (BE, LU);",
"     </li>",
"     <li>",
"      Valontan (ES, IT);",
"     </li>",
"     <li>",
"      Vertirosan (AT);",
"     </li>",
"     <li>",
"      Vomidrine (PT);",
"     </li>",
"     <li>",
"      Vomisin (MX);",
"     </li>",
"     <li>",
"      Votmine (MY);",
"     </li>",
"     <li>",
"      Xamamina (IT);",
"     </li>",
"     <li>",
"      Yi Han Ning (CL);",
"     </li>",
"     <li>",
"      Zoranate (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dimenhydrinate is a salt of two drugs: Diphenhydramine (53% to 55.5%) and 8-chlorotheophylline (44% to 47%). Refer to DiphenhydrAMINE (Systemic) monograph.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG (American College of Obstetricians and Gynecologists), \"Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12006/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12006/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8896 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12006=[""].join("\n");
var outline_f11_46_12006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160747\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160748\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160786\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160752\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160767\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160753\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160736\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160724\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7694532\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160737\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446198\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160790\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160784\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160740\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160728\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299204\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160732\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160746\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160733\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446199\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7694529\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446200\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160741\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422223\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160742\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160727\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160739\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/50/34596?source=related_link\">",
"      Dimenhydrinate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/15/11509?source=related_link\">",
"      Dimenhydrinate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_46_12007="Atomoxetine: Pediatric drug information";
var content_f11_46_12007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atomoxetine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"    see \"Atomoxetine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=see_link\">",
"    see \"Atomoxetine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Strattera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atomoxetine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Atomoxetine;",
"     </li>",
"     <li>",
"      PMS-Atomoxetine;",
"     </li>",
"     <li>",
"      Sandoz-Atomoxetine;",
"     </li>",
"     <li>",
"      Strattera&reg;;",
"     </li>",
"     <li>",
"      Teva-Atomoxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Norepinephrine Reuptake Inhibitor, Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"      see \"Atomoxetine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents, weighing &le;70 kg: Oral: Initial: 0.5 mg/kg/day; increase after a minimum of 3 days to ~1.2 mg/kg/day; may administer once daily in the morning or divide into 2 doses and administer in the morning and late afternoon/early evening; maximum daily dose: 1.4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 100 mg/",
"     <b>",
"      day",
"     </b>",
"     , whichever is less.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;1.2 mg/kg/day have not been shown to provide additional benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Initial: 0.5 mg/kg/day dose for 4 weeks; increase dose to 1.2 mg/kg/day only if clinically needed and the initial dose is well tolerated; do not exceed 1.2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents, weighing &gt;70 kg and Adults: Oral: Initial: 40 mg daily; increase after a minimum of 3 days to ~80 mg daily; may administer once daily in the morning or divide into 2 doses and administer in morning and late afternoon/early evening. After an additional 2-4 weeks, may increase (if needed) to maximum daily dose: 100 mg/",
"     <b>",
"      day",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Initial 40 mg daily dose for 4 weeks; increase dose to 80 mg daily only if clinically needed and the initial dose is well tolerated; do not exceed 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults:  No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hepatic impairment (Child-Pugh class B): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Administer 25% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strattera&reg;: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food. Do not crush, chew, or open capsule; swallow whole with water or other liquids.",
"     <b>",
"      Note:",
"     </b>",
"     Atomoxetine is an ocular irritant; if capsule is opened accidently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8002173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       AtoMOXetine may be confused with atorvaSTATin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Diastolic pressure increased, flushing, orthostatic hypotension, palpitation, systolic blood pressure increased, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fatigue/lethargy, headache, insomnia, irritability, mood swings, sleep disturbance, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, hot flashes, libido decreased, menstruation disturbance, orgasm abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, dyspepsia, nausea, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Erectile disturbance, dysuria, ejaculatory disturbance, prostatitis, urinary hesitation/retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sinus headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Jittery feeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressiveness, agitation, akathisia, allergic reactions, allergy, anaphylaxis, angioedema, anxiety, delusional thinking, depression, flatulence, growth suppression (children), hallucinations, hepatotoxicity, hostility, hyperhidrosis, hypoesthesia, hypomania, impulsiveness, jaundice, mania, MI, panic attacks, paresthesia, pelvic pain, peripheral vascular instability, priapism, pruritus, QT prolongation, Raynaud&rsquo;s phenomenon, seizure (including patients with no prior history or known risk factors for seizure), stroke, suicidal ideation, syncope, tics, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atomoxetine or any component; concurrent use or use within 14 days of MAO inhibitors; narrow-angle glaucoma; current or past history of pheochromocytoma; severe cardiovascular disorders in which the condition would be expected to deteriorate with clinically relevant blood pressure or heart rate increases.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause orthostatic hypotension or syncope; use with caution in patients with conditions that predispose to hypotension or with conditions associated with abrupt heart rate or blood pressure changes. May cause new onset or exacerbation of Raynaud's phenomenon. May cause urinary retention or hesitancy; use with caution in patients with a history of urinary retention or bladder outlet obstruction. May rarely cause priapism; prompt medical attention may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients who are cytochrome P450 CYP2D6 poor metabolizers; bioavailablity and drug exposure may be increased; dosage adjustments are recommended; the incidence of some adverse reactions are reported to be increased in poor metabolizers of CYP2D6 substrates including decreased appetite, increases in blood pressure or heart rate,  insomnia, sedation, depression, tremor, early morning awakening, pruritus, and mydriasis. Use caution with concurrent use of strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, and quinidine); modification of atomoxetine dose may be required.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atomoxetine has been associated with an increased risk of suicidal thinking in children and adolescents with ADHD",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . This risk must be considered before prescribing atomoxetine in pediatric patients. Children and adolescents who start treatment with atomoxetine require close monitoring for suicidal thinking and behavior (ie, suicidality), unusual changes in behavior, or clinical worsening, especially during the first few months after initiation of a course of therapy or when the dosage is changed. Family members and caregivers should be instructed to closely observe the patient and communicate their condition with the healthcare provider. Recommended monitoring includes daily observation by family members and caregivers. Patients should also be monitored for associated behaviors (eg, agitation, irritability, anxiety, akathisia, aggressiveness, insomnia, hostility, impulsivity, panic attacks, hypomania, mania) which may be precursors to emerging suicidality. Emergence of suicidality or associated behaviors listed above, that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Psychiatric adverse events may occur. Atomoxetine may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur in patients without a prior history of psychotic illness or mania, even at standard doses. Atomoxetine may induce mixed/manic episodes in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. New or worsening symptoms of hostility or aggressive behaviors have been associated with atomoxetine (causal relationship not established) particularly with the initiation of therapy; monitor for development or worsening of these behaviors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rare, severe liver injury has been reported with atomoxetine including liver failure (requiring transplantation) and death; the majority of cases occurred within 120 days of initiation of therapy; discontinue atomoxetine and do not restart if signs or symptoms of hepatotoxic reaction (eg, jaundice, pruritus, flu-like symptoms) or laboratory evidence of liver injury are  observed. Use with caution in patients with hepatic impairment; dosage adjustments may be necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of atomoxetine in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the noradrenergic effects of atomoxetine. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as atomoxetine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers. It  should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause increases in blood pressure and heart rate; in pediatric clinical trials, incidences of maximum increases in SBP, DBP, and HR compared to placebo were as follows: SBP (&ge;20 mm Hg): 12.5% vs 8.7%; DBP (&ge;15 mm Hg): 21.5% vs 14.1%; and HR (&ge;20 bpm): 23.4% vs 11.5%; monitor blood pressure and pulse at baseline, with dosage increases, and periodically during therapy. Use caution in patients with underlying medical conditions which may be exacerbated by increases in blood pressure and/or heart rate, including hypertension, tachycardia, or other cardiovascular or cerebrovascular conditions; use is contraindicated in patients with severe cardiovascular disorders who may experience clinical deterioration of condition with clinical increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Allergic reactions (including anaphylaxis, rash, urticaria, and angioneurotic edema) may occur (rare).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In pediatric patients, suppression of growth (height and weight) has been reported during the initial 9-12 months of therapy and has been shown to recover to normative values by 3 years of therapy; this growth pattern has been observed to be independent of pubertal status and patient&rsquo;s metabolic profile (ie, poor or extensive metabolizer); growth should be monitored during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: AtoMOXetine may enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of AtoMOXetine. Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Antidepressants (Selective Norepinephrine Reuptake Inhibitor) may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A high fat meal decreases the rate, but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased pup weight and survival were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit to the mother outweighs possible risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Family members and caregivers need to monitor patient daily for emergence of irritability, agitation, unusual changes in behavior, and suicide ideation. Pediatric patients should be monitored closely for suicidality, clinical worsening, or unusual changes in behavior, especially during the initial few months of therapy or at times of dose changes. Appearance of symptoms needs to be immediately reported to healthcare provider.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Evaluate for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor body weight, BMI, height and growth rate (in children); CNS activity; blood pressure and heart rate and rhythm (baseline, following dose increases, and periodically during treatment); liver enzymes in patients with symptoms of liver dysfunction; sleep, appetite, abnormal movements. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Monitor for new psychotic symptoms, appearance or worsening of aggressive behavior, or hostility.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enhances norepinephrine activity by selectively inhibiting norepinephrine reuptake; little to no activity at other neuronal reuptake pumps or receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The pharmacokinetics  in pediatric patients &ge;6 years of age have been shown to be similar to those of adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 0.85 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2D6 and CYP2C19, then glucaronidation. Metabolites include: 4-hydroxyatomoxetine (active, equipotent to atomoxetine) and N-desmethlyatomoxetine (in poor metabolizers, limited activity).",
"     <b>",
"      Note:",
"     </b>",
"     CYP2D6 poor metabolizers have atomoxetine AUCs that are ~10-fold higher and peak concentrations that are ~fivefold greater than extensive metabolizers; 4-hyroxyatomoxetine plasma concentrations are very low (extensive metabolizers: 1% of atomoxetine concentrations; poor metabolizers: 0.1% of atomoxetine concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Extensive metabolizers: 63%; poor metabolizers: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atomoxetine: Extensive metabolizers: 5.2 hours; poor metabolizers: 21.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-hydroxyatomoxetine: Extensive metabolizers: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desmethlyatomoxetine: Extensive metabolizers: 6-8 hours; poor metabolizers: 34-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 1-2 hours; delayed 3 hours by high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine: &lt;3% is excreted unchanged; 80% excreted as 4-hydroxyatomoxetine glucuronide; feces: &lt;17%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=see_link\">",
"      see \"Atomoxetine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An increased risk of suicidal thinking and behavior has been reported with the use of atomoxetine in children and adolescents; notify physician if  depression, thoughts of suicide, or agitation or irritability occur. Read the patient Medication Guide received with each prescription and refill of atomoxetine. Cases of sudden death and other heart problems have been reported in patients with heart defects or heart problems; inform physician of  any heart defect, heart problems, high or low blood pressure, or a family history of these problems. Inform physician of  allergies, narrow-angle glaucoma, or current or past liver problems. Notify physician of rapid or irregular heartbeats, dark urine, yellow skin or eyes, abdominal pain, itching, unexplained flu-like symptoms, new psychotic symptoms (eg, hearing voices), or an increase in aggression or hostility. Some medicines should not be taken with atomoxetine; report the use of other medications, nonprescription medications, and herbal or natural products. If a dose is missed, take it as soon as possible, but do not take more than the prescribed total daily amount in any 24-hour period. May cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination; may cause weight loss; may cause decreased growth in children; may make it difficult to urinate; may cause dry mouth; may rarely cause prolonged (&gt;4 hours) penile erections (seek prompt medical attention). Do not open capsules or allow capsule or contents to come into contact with eye; if capsule contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atomoxetine hydrochloride is the R(-) isomer. Therapy may be discontinued without being tapered. Total daily doses &gt;150 mg/day and single doses &gt;120 mg/dose have not been systematically evaluated. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. If used for an extended period of time, long-term usefulness of atomoxetine should be periodically re-evaluated for the individual patient.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 128(5):1007-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biderman J, Heiligenstein JH, Faries DE, at al, &ldquo;Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 110(6), file://www.pediatrics.org/cgi/content/full/110/6/e75.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA and Pliszka SR, \"Attention-Deficit-Hyperactivity Disorder: An Update,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(6):656-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/19476419/pubmed\" id=\"19476419\" target=\"_blank\">",
"        19476419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kratochvil CJ, Heiligenstein JH, Dittmann R, et al, &ldquo;Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2002, 41(7):776-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/12108801/pubmed\" id=\"12108801\" target=\"_blank\">",
"        12108801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michelson D, Allen AJ, Busner J, et al, &ldquo;Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2002, 159(11):1896-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/12411225/pubmed\" id=\"12411225\" target=\"_blank\">",
"        12411225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michelson D, Faries D, Wernicke J, et al, &ldquo;Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Ramdomized, Placebo-Controlled, Dose-Response Study,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(5), file://www.pediatrics.org/cgi/content/full/108/5/e83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/11694667 /pubmed\" id=\"11694667 \" target=\"_blank\">",
"        11694667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newcorn JH, Michelson D, Kratochvil CJ, et al, \"Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(6):e1701-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/17101710/pubmed\" id=\"17101710\" target=\"_blank\">",
"        17101710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer T, Heiligenstein JH, Biederman J, et al, &ldquo;Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2002, 63(12):1140-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/12523874/pubmed\" id=\"12523874\" target=\"_blank\">",
"        12523874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wernicke JF and Kratochvil CJ, &ldquo;Safety Profile of Atomoxetine in the Treatment of Children and Adolescents With ADHD,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2002, 63(Suppl 12):50-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/46/12007/abstract-text/ 12562062 /pubmed\" id=\" 12562062 \" target=\"_blank\">",
"        12562062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13048 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12007=[""].join("\n");
var outline_f11_46_12007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708625\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137799\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855136\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051253\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051246\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137779\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137765\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874384\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051257\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051249\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051256\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137822\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051260\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051245\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051244\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137773\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051263\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137775\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137786\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051252\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051243\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051259\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051251\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051261\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=related_link\">",
"      Atomoxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=related_link\">",
"      Atomoxetine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_46_12008="Olfactory neuroblastoma (esthesioneuroblastoma)";
var content_f11_46_12008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Olfactory neuroblastoma (esthesioneuroblastoma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Carl Snyderman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Derrick Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12008/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/46/12008/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory neuroblastoma (ONB), also referred to as esthesioneuroblastoma, is a rare malignant tumor of neuroectodermal origin. Olfactory neuroblastomas are thought to arise from the olfactory epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, pathology, treatment, and follow-up of patients with olfactory neuroblastomas will be reviewed here. Other malignancies of the nasal cavity and skull base are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most representative data on the epidemiology of olfactory neuroblastomas come from an analysis of 311 cases in the Surveillance, Epidemiology, and End Results (SEER) database over a 30 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/2\">",
"     2",
"    </a>",
"    ]. In this study, the mean age at presentation was 53 years, with most cases occurring in patients between 40 and 70 years. There was a moderate male predominance with a 55:45 male:female ratio.",
"   </p>",
"   <p>",
"    Other small, contemporary single institution series have yielded similar observations regarding age and gender distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms are related to the presence of a nasal mass. Symptoms can also be due to invasion of adjacent structures.",
"   </p>",
"   <p>",
"    Nasal obstruction due to the presence of a mass is the most common symptom and is present in the majority of cases. Physical examination usually reveals a red-brown, polypoid mass located high in the nasal cavity. Other manifestations of local disease include epistaxis, nasal discharge,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain.",
"   </p>",
"   <p>",
"    Early diagnosis is uncommon. Olfactory neuroblastomas are generally slow growing tumors and symptoms are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In a SEER database study that included 261 cases with sufficient data to permit staging, only 17 percent had disease confined to the nasal cavity while 54 percent had local disease extending beyond the nasal cavity and 29 percent had regional or distant metastases (Kadish stages A, B plus C, and D, respectively, (",
"    <a class=\"graphic graphic_table graphicRef57376 \" href=\"UTD.htm?2/24/2443\">",
"     table 1",
"    </a>",
"    ))&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Examples of symptoms due local extension of tumor include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anosmia can be caused by tumor extension into the cribriform plate",
"     </li>",
"     <li>",
"      Pain, proptosis, and excessive lacrimation, due to orbital extension",
"     </li>",
"     <li>",
"      Ear pain and otitis media, because of obstruction of the eustachian tube",
"     </li>",
"     <li>",
"      Frontal headache, due to involvement of the frontal sinus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with olfactory neuroblastomas may have paraneoplastic syndromes due to ectopic hormone production, including ectopic adrenocorticotropic hormone syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/3,8\">",
"     3,8",
"    </a>",
"    ], hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/9\">",
"     9",
"    </a>",
"    ], and hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs may reveal an intranasal soft tissue density. When the tumor is more extensive, bone destruction and opacification of paranasal sinuses may be seen. Computed tomography (CT) and magnetic resonance imaging (MRI) help to differentiate tumor from other causes of nasal obstruction and are useful for tumor staging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT provides the best information about invasion into bony structures and permits detailed assessment of bony erosion or destruction, particularly of the cribriform plate.",
"     </li>",
"     <li>",
"      MRI is more accurate for defining the margins of intracranial tumor extension into adjacent soft tissue areas, such as the anterior cranial fossa and the retromaxillary space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging studies cannot differentiate olfactory neuroblastomas from other tumors. Definitive diagnosis requires histologic examination of a biopsy or surgical specimen and may require electron microscopy and immunohistochemistry. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniformly accepted staging system for patients with olfactory neuroblastoma.",
"   </p>",
"   <p>",
"    The most widely used approach is the Kadish clinical staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/13\">",
"     13",
"    </a>",
"    ]. As originally proposed, this was a three-tier classification based upon the extent of the primary tumor. This was subsequently modified to include a separate category for patients with lymph node or distant metastases (",
"    <a class=\"graphic graphic_table graphicRef57376 \" href=\"UTD.htm?2/24/2443\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A &mdash; confined to the nasal cavity",
"     </li>",
"     <li>",
"      Stage B &mdash; involvement of one or more paranasal sinuses",
"     </li>",
"     <li>",
"      Stage C &mdash; extension beyond the nasal cavity and paranasal sinuses",
"     </li>",
"     <li>",
"      Stage D &mdash; regional lymph node or distant metastasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another staging system, the Dulguerov system, is based upon a TNM type of classification and uses CT scanning and MR imaging to ascertain the local disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On gross examination, olfactory neuroblastoma is a polypoid, soft, and hemorrhagic tumor. Microscopically, sheets or discrete nests or lobules of small round cells slightly larger than lymphocytes are present, which are often compartmentalized into nodules by thin fibrous septa (",
"    <a class=\"graphic graphic_picture graphicRef50794 \" href=\"UTD.htm?3/37/3671\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The tumor cells have hyperchromatic nuclei with uniform chromatin distribution, small inconspicuous nucleoli, and sparse cytoplasm. The stroma is typically pink, neurofibrillary or edematous, and well vascularized. Mitoses are rare.",
"   </p>",
"   <p>",
"    Homer Wright pseudorosettes, which are composed of tumor cells surrounding a central pink fibrillar material, are seen in one-half of olfactory neuroblastomas; true (Flexner type) rosettes, composed of tumor cells surrounding a central lumen, are infrequent. Necrosis, dystrophic calcification, and vascular or lymphatic invasion are not uncommon. In rare instances, a few admixed ganglion cells may be seen. Cytoplasmic glycogen is absent and reticulin fibers surround the tumor lobules, rather than individual tumor cells. Electron microscopy of olfactory neuroblastomas demonstrates cytoplasmic neurofilaments, neurotubules, mitochondria, and dense-core neurosecretory granules (100 to 200 nm in diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Hyams histologic grading system grades tumors from I to IV based upon pathologic features such as mitotic activity and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I tumors are characterized by a prominent fibrillary matrix, tumor cells with uniform nuclei and absence of nuclear pleomorphism, mitotic activity, or necrosis.",
"     </li>",
"     <li>",
"      Grade II tumors have some fibrillary matrix and exhibit moderate nuclear polymorphism with some mitotic activity. There is no necrosis.",
"     </li>",
"     <li>",
"      Grade III tumors have minimal fibrillary matrix and Flexner type rosettes are present. There is prominent mitotic activity and nuclear polymorphism and some necrosis may be seen.",
"     </li>",
"     <li>",
"      Grade IV tumors have no fibrillary matrix or rosettes and show marked nuclear pleomorphism and increased mitotic activity with frequent necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have found a correlation between Hyams grade and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/12,15,16,19\">",
"     12,15,16,19",
"    </a>",
"    ]. In a meta-analysis that included five studies in which lesions were graded histologically, the mean five-year survival was 56 percent for those with low-grade lesions (Hyams I and II) versus 20 percent for those with high-grade lesions (Hyams III and IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other small round blue cell tumors can present in the sinonasal region. Many can be distinguished from olfactory neuroblastoma on light microscopic features alone but, in some instances, additional techniques such as immunohistochemistry are useful. &nbsp;Olfactory neuroblastoma must be differentiated from related tumors such as neuroendocrine carcinoma and sinonasal undifferentiated carcinoma since the biological behavior, treatment, and prognosis may differ. &nbsp;",
"   </p>",
"   <p>",
"    Immunohistochemically, olfactory neuroblastomas typically stain for neuron-specific enolase (NSE); approximately 65 percent of tumors stain for synaptophysin, and a lesser proportion for chromogranin. In some cases, tumor cells may be positive for neurofilament or cytokeratin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. The supporting or sustentacular cells may be positive for S-100 protein or glial fibrillary acidic protein (GFAP). Tumor cells are negative for a variety of other markers, such as epithelial membrane antigen (EMA), leukocyte common antigen, kappa and lambda light chains, HMB45, desmin, myoglobin, vimentin, and MIC2 (CD99), the Ewing sarcoma marker [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other tumors that may be confused with olfactory neuroblastoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinonasal undifferentiated carcinoma &mdash; Sinonasal undifferentiated carcinoma (SNUC) is an aggressive neoplasm that is derived from Schneiderian epithelium. It is composed of medium-sized, polygonal cells with round to oval hyperchromatic nuclei and a scant to moderate amount of eosinophilic cytoplasm. Tumor cells are arranged in nests, wide trabeculae, ribbons and sheets, with surface dysplasia. Mitoses, necrosis and vascular invasion are often present [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. Neurofibrillary stroma and pseudorosettes are absent, but sparse neurosecretory granules may be seen. Tumor cells are reactive for cytokeratin (90 percent) and EMA (65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"       \"Pathology of head and neck neoplasms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhabdomyosarcoma &mdash; Rhabdomyosarcoma (RMS) is distinguished from other malignant neoplasms by evidence of skeletal muscle differentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. The diagnosis is typically made by finding rhabdomyoblasts and cross striations on routine sections,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrastructural studies demonstrating actin and myosin filaments with Z band and intermediate filaments. Immunostaining provides corroborative evidence. Over 90 percent of RMSs are positive for desmin and 50 to 90 percent for myoglobin. A smaller number express cytokeratin and S-100 protein. Another useful diagnostic aid is the presence of a consistent chromosomal rearrangement, t(2;13) (q35;q14) in the alveolar type of RMS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ewing sarcoma &mdash; Ewing sarcoma and related primitive neuroectodermal tumors (PNET) are characterized by the chromosomal translocation t(11;22) (q24;q12) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, Ewing sarcoma is MIC2 (CD99) positive. In one study of 69 round cell lesions of the sinonasal region (22 olfactory neuroblastomas, 17 malignant lymphomas, nine Ewing sarcomas, nine RMSs, three sinonasal undifferentiated carcinomas, five melanomas, and four pituitary adenomas), each of the cases of Ewing sarcoma was positive for MIC2; all other tumors were MIC2 negative [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/31\">",
"       31",
"      </a>",
"      ]. Olfactory neuroblastomas also lack the Ewing sarcoma chromosomal translocation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized clinical trials in patients with olfactory neuroblastomas and observational studies have limited numbers of patients due to the rarity of this disease. In addition, the natural history of the disease necessitates prolonged observation to adequately assess the results of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, surgery, radiation therapy (RT),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy have all been used in the treatment of primary olfactory neuroblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/34\">",
"     34",
"    </a>",
"    ]. Observational studies generally indicate that combining surgery and RT has resulted in prolonged disease-free and overall survival compared to either surgery or RT alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of olfactory neuroblastomas originally used a transfacial approach. However, multiple observational studies found that a combined craniofacial approach improved the ability to achieve an en bloc resection and resulted in better local control of disease and improved survival compared to a transfacial approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/15,19,34,35\">",
"     15,19,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recent advances in surgical techniques have led to the development of a minimally invasive endoscopic approach in carefully selected patients as a way to minimize complications and improve the cosmetic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. A meta-analysis of olfactory neuroblastoma that included 361 patients in 23 published studies demonstrated a greater published survival rate for endoscopic surgery compared to open surgery, even when taking into account the year of publication [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/40\">",
"     40",
"    </a>",
"    ]. Although the patient groups had similar follow-up, patients treated with endoscopic surgery had earlier stage tumors, suggesting a selection bias. The availability and preference of surgical approach varies between institutions. This surgical technique may be combined with a neurosurgical approach for the intracranial component of disease or with radiation therapy (RT).",
"   </p>",
"   <p>",
"    Currently, surgery alone for the initial management of patients with an olfactory neuroblastoma is generally restricted to carefully selected patients with Kadish stage A olfactory neuroblastoma, because of the high risk of local recurrence and the better results of a combined modality approach that includes RT. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surgery plus RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) alone has been used for the initial treatment of patients with olfactory neuroblastoma in a number of series, but results have generally been less satisfactory that when RT is used in combination with surgery.",
"   </p>",
"   <p>",
"    A review of the literature identified 55 cases of olfactory neuroblastoma treated with RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/41\">",
"     41",
"    </a>",
"    ]. Treatment was successful in preventing disease recurrence in all six cases with Kadish stage A disease at a median follow-up of over eight years. However for patients with more extensive disease (Kadish stage B and C disease), treatment was successful in only 7 of 12 (58 percent) and 7 of 37 (19 percent) cases, respectively.",
"   </p>",
"   <p>",
"    Newer radiotherapy techniques, such as intensity modulated radiation therapy (IMRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/42\">",
"     42",
"    </a>",
"    ] and proton beam therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/34,43\">",
"     34,43",
"    </a>",
"    ] may be more effective at minimizing toxicity to normal structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Surgery plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combined otolaryngologic and neurosurgical anterior craniofacial resection followed by postoperative radiotherapy is the most widely used approach for patients with localized olfactory neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/3,4,6,19,34,44,45\">",
"     3,4,6,19,34,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results with this approach are illustrated by a literature review and meta-analysis that included 390 patients from 26 studies published between 1990 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/19\">",
"     19",
"    </a>",
"    ]. For the 169 patients treated with a combination of surgery and RT, the reported survival was 65 percent. The reported survival rates for the 87 patients treated with surgery alone and the 49 patients treated with radiation alone were 48 and 37 percent, respectively.",
"   </p>",
"   <p>",
"    The use of a combined modality approach is particularly important for patients in whom disease extends beyond the paranasal sinuses (Kadish stage C, (",
"    <a class=\"graphic graphic_table graphicRef57376 \" href=\"UTD.htm?2/24/2443\">",
"     table 1",
"    </a>",
"    )) or in whom surgical resection margins are positive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single institution series of 30 cases managed predominantly with craniofacial resection and postoperative RT, there were no recurrences in the 11 patients with Kadish A or B disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/4\">",
"       4",
"      </a>",
"      ]. Among the 19 cases with Kadish C olfactory neuroblastomas, nine patients eventually recurred; the 5 and 10-year relapse-free survival rates were 61 and 0 percent, respectively.",
"     </li>",
"     <li>",
"      In another series of 10 patients managed with craniofacial resection and postoperative proton beam RT, all five patients with negative resection margins remained free of disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/34\">",
"       34",
"      </a>",
"      ]. However, four of the five patients with positive margins eventually recurred, including three after a disease-free interval of more than five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chemotherapy, either before or after RT or surgery, is unclear. Numerous studies have used various chemotherapy regimens in an effort to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. However, it is unclear whether this actually improves results compared with a combined craniofacial resection and RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neck disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases to cervical lymph nodes are the most frequent site of olfactory neuroblastoma dissemination. In a meta-analysis of 26 studies that included 390 patients, concurrent neck metastases were present in 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment of patients with neck metastases was successful significantly less frequently than in those without neck metastases (29 versus 64 percent).",
"   </p>",
"   <p>",
"    Delayed cervical lymph node involvement is also frequent. The incidence and management of neck metastases occurring at least six months after diagnosis were analyzed in a review of the literature that included 678 patients with olfactory neuroblastoma identified in 33 articles published since 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, cervical lymph node metastases were identified in 137 patients (20 percent). For 79 patients (12 percent), cervical lymph node involvement was identified at least six months after the diagnosis of an olfactory neuroblastoma.",
"     </li>",
"     <li>",
"      Results of salvage treatment were available for 45 patients who had a delayed relapse in cervical lymph nodes. For patients managed with a combination of surgery plus RT, 10 of 17 patients (71 percent) remained disease-free for at least one year after salvage therapy. Results with either surgery alone or RT alone were significantly worse (3 of 19 [21 percent] and one of nine [11 percent], respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarity of olfactory neuroblastomas, combined with the favorable prognosis following aggressive local regional therapy, has resulted in only very limited experience for patients with disseminated disease. Cytotoxic chemotherapy appears to have activity in some patients, and newer molecularly targeted approaches may become an option as the biology of olfactory neuroblastomas is better understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of chemotherapy agents have been evaluated in small series. These reports have included a mixture of patients with disseminated disease and with locoregional disease where chemotherapy was used alone or in combination with surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based combination regimens (particularly cisplatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) have often been chosen, primarily because of their activity in patients with head and neck squamous cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/5,52-61\">",
"     5,52-61",
"    </a>",
"    ]. Nonplatinum combinations, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , may also be active [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Responses in patients with disseminated disease have generally been of short duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the molecular pathogenesis of olfactory neuroblastomas may lead to the use of targeted therapies in patients with advanced disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case report, treatment of a patient with advanced olfactory neuroblastoma using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      resulted in stabilization of disease for 15 months after progression following maximal surgery and RT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/62\">",
"       62",
"      </a>",
"      ]. Immunohistochemistry of a tumor biopsy revealed expression of platelet-derived growth factor.",
"     </li>",
"     <li>",
"      Signaling in the sonic hedgehog pathway has been associated with tumor cell growth in patients with nevoid basal cell carcinoma and some other tumors. In at least one report, key genes in this pathway were activated in olfactory neuroblastoma cell lines, but not in normal olfactory epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/63\">",
"       63",
"      </a>",
"      ]. If this observation is confirmed, this may offer another target for specific therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"       \"Nevoid basal cell carcinoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POST TREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal guidelines for appropriate follow-up after treatment for olfactory neuroblastoma. Multiple studies have documented that local or regional recurrences can occur for at least 10 to 15 years after initial therapy. Treatment of such recurrences appears to be associated with prolonged disease-free survival in some of these cases.",
"   </p>",
"   <p>",
"    Based upon this observation, extended clinical and imaging follow-up is indicated in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12008/abstract/3,4,6,34\">",
"     3,4,6,34",
"    </a>",
"    ]. Our approach is to do a baseline MRI at two to three months after treatment. MRI is then repeated at six month intervals for about two years, followed by yearly examinations until the five year mark.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a slow growing neuroectodermal malignancy of the nasal cavity, which usually presents with locally invasive disease. Olfactory neuroblastomas have a marked tendency for late local and regional recurrences.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with Kadish stage A tumors (",
"      <a class=\"graphic graphic_table graphicRef57376 \" href=\"UTD.htm?2/24/2443\">",
"       table 1",
"      </a>",
"      ), we suggest a combination of surgical excision and radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery alone may be a suitable alternative for carefully selected patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with Kadish B and Kadish C primary tumors, we suggest a combination of surgery and RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In observational series, this approach has resulted in improved overall survival compared to either surgery or RT alone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with olfactory neuroblastoma may develop recurrences ten or more years following initial treatment. Thus, prolonged surveillance for evidence of local or regional recurrence is indicated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Post treatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aggressive local therapy, with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT is indicated for patients with a local recurrence without distant metastases, since a significant number of such patients may have prolonged disease-free survival.",
"     </li>",
"     <li>",
"      Surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT is indicated for patients with cervical lymph node recurrence. Aggressive therapy in this setting can result in prolonged disease-free survival in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic treatment may provide clinically useful palliation of patients with advanced olfactory neuroblastoma who are not candidates for definitive surgery or RT. There are insufficient data to recommend any specific chemotherapy regimen; such patients should be enrolled in clinical protocols whenever feasible. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Neuroectodermal tumours. In: Pathology and genetics of head and neck tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon, France 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/2\">",
"      Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/3\">",
"      Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience. Skull Base 2009; 19:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/4\">",
"      Diaz EM Jr, Johnigan RH 3rd, Pero C, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 2005; 27:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/5\">",
"      Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 2000; 22:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/6\">",
"      Bachar G, Goldstein DP, Shah M, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/7\">",
"      Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/8\">",
"      Koo BK, An JH, Jeon KH, et al. Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review. Endocr J 2008; 55:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/9\">",
"      Sharma S, Lasheen W, Walsh D. Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma. Rhinology 2008; 46:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/10\">",
"      Pickuth D, Heywang-K&ouml;brunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol Allied Sci 1999; 24:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/11\">",
"      Derdeyn CP, Moran CJ, Wippold FJ 2nd, et al. MRI of esthesioneuroblastoma. J Comput Assist Tomogr 1994; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/12\">",
"      Kairemo KJ, Jekunen AP, Kestil&auml; MS, Ramsay HA. Imaging of olfactory neuroblastoma--an analysis of 17 cases. Auris Nasus Larynx 1998; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/13\">",
"      Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/14\">",
"      Morita A, Ebersold MJ, Olsen KD, et al. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/15\">",
"      Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102:843.",
"     </a>",
"    </li>",
"    <li>",
"     Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. In: Atlas of Tumor Pathology, Armed Forces Institute of Pathology, 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/17\">",
"      Hirose T, Scheithauer BW, Lopes MB, et al. Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. Cancer 1995; 76:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/18\">",
"      Lund VJ, Milroy C. Olfactory neuroblastoma: clinical and pathological aspects. Rhinology 1993; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/19\">",
"      Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/20\">",
"      Frierson HF Jr, Ross GW, Mills SE, Frankfurter A. Olfactory neuroblastoma. Additional immunohistochemical characterization. Am J Clin Pathol 1990; 94:547.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes L, Peel RL. Olfactory neuroblastomas versus sinonasal undifferentiated carcinoma. In: Head and Neck Pathology. A Text/Atlas of Differential Diagnosis, Igaku-Shoin, New York 1990. p.152.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/22\">",
"      Frierson HF Jr, Mills SE, Fechner RE, et al. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 1986; 10:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/23\">",
"      Mills SE, Fechner RE. \"Undifferentiated\" neoplasms of the sinonasal region: differential diagnosis based on clinical, light microscopic, immunohistochemical, and ultrastructural features. Semin Diagn Pathol 1989; 6:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/24\">",
"      Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 1988; 6:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/25\">",
"      Kodet R, Newton WA Jr, Hamoudi AB, et al. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol 1993; 17:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/26\">",
"      Dickman PS, Triche TJ. Extraosseous Ewing's sarcoma versus primitive rhabdomyosarcoma: diagnostic criteria and clinical correlation. Hum Pathol 1986; 17:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/27\">",
"      Parham DM, Webber B, Holt H, et al. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms. Results of an Intergroup Rhabdomyosarcoma study project. Cancer 1991; 67:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/28\">",
"      Douglass EC, Shapiro DN, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993; 21:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/29\">",
"      Whang-Peng J, Knutsen T, Theil K, et al. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer 1992; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/30\">",
"      de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/31\">",
"      Devaney K, Wenig BM, Abbondanzo SL. Olfactory neuroblastoma and other round cell lesions of the sinonasal region. Mod Pathol 1996; 9:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/32\">",
"      Mezzelani A, Tornielli S, Minoletti F, et al. Esthesioneuroblastoma is not a member of the primitive peripheral neuroectodermal tumour-Ewing's group. Br J Cancer 1999; 81:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/33\">",
"      Simon JH, Zhen W, McCulloch TM, et al. Esthesioneuroblastoma: the University of Iowa experience 1978-1998. Laryngoscope 2001; 111:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/34\">",
"      Nichols AC, Chan AW, Curry WT, et al. Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base 2008; 18:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/35\">",
"      Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: the University of Virginia experience 1960-1985. Laryngoscope 1986; 96:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/36\">",
"      Unger F, Haselsberger K, Walch C, et al. Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wien) 2005; 147:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/37\">",
"      Folbe A, Herzallah I, Duvvuri U, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy 2009; 23:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/38\">",
"      Kim BJ, Kim DW, Kim SW, et al. Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base. Clin Exp Otorhinolaryngol 2008; 1:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/39\">",
"      Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/40\">",
"      Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope 2009; 119:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/41\">",
"      Benfari G, Fusconi M, Ciofalo A, et al. Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital 2008; 28:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/42\">",
"      Madani I, Bonte K, Vakaet L, et al. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/43\">",
"      Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys 2007; 68:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/44\">",
"      Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future? Laryngoscope 2003; 113:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/45\">",
"      Theilgaard SA, Buchwald C, Ingeholm P, et al. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/46\">",
"      Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002; 94:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/47\">",
"      Eich HT, Hero B, Staar S, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol 2003; 179:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/48\">",
"      Zappia JJ, Carroll WR, Wolf GT, et al. Olfactory neuroblastoma: the results of modern treatment approaches at the University of Michigan. Head Neck 1993; 15:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/49\">",
"      Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/50\">",
"      Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope 2003; 113:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/51\">",
"      Gore MR, Zanation AM. Salvage treatment of late neck metastasis in esthesioneuroblastoma: a meta-analysis. Arch Otolaryngol Head Neck Surg 2009; 135:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/52\">",
"      Weiden PL, Yarington CT Jr, Richardson RG. Olfactory neuroblastoma. Chemotherapy and radiotherapy for extensive disease. Arch Otolaryngol 1984; 110:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/53\">",
"      Sheehan JM, Sheehan JP, Jane JA Sr, Polin RS. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000; 11:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/54\">",
"      Mishima Y, Nagasaki E, Terui Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. Cancer 2004; 101:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/55\">",
"      Wade PM Jr, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer 1984; 53:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/56\">",
"      McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998; 42:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/57\">",
"      Chamberlain MC. Treatment of intracranial metastatic esthesioneuroblastoma. Cancer 2002; 95:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/58\">",
"      Heros DO, Hochberg FH. Treatment of esthesioneuroblastoma with chemotherapy: a report of two cases. J Neurooncol 1988; 6:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/59\">",
"      Kim DW, Jo YH, Kim JH, et al. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004; 101:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/60\">",
"      Kiyota N, Tahara M, Fujii S, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. Cancer 2008; 112:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/61\">",
"      Turano S, Mastroianni C, Manfredi C, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol 2010; 98:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/62\">",
"      Preusser M, Hutterer M, Sohm M, et al. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol 2010; 97:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12008/abstract/63\">",
"      Mao L, Xia YP, Zhou YN, et al. Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology 2009; 77:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5183 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12008=[""].join("\n");
var outline_f11_46_12008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Surgery plus RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neck disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Systemic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POST TREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5183|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/37/3671\" title=\"picture 1\">",
"      Olfactory neuroblastoma Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/24/2443\" title=\"table 1\">",
"      Kadish staging ONB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_46_12009="Diagnosis of latent tuberculosis infection in HIV-infected patients";
var content_f11_46_12009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of latent tuberculosis infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Madhukar Pai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Dick Menzies, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12009/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/46/12009/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/46/12009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1873885\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of the world&rsquo;s population is estimated to be latently infected with Mycobacterium tuberculosis, representing a major reservoir of potential active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/1\">",
"     1",
"    </a>",
"    ]. The intersection of the HIV and tuberculosis (TB) epidemics has led to a major upsurge in TB cases, particularly in resource-limited settings where TB is prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the risk of active TB disease in HIV-infected patients can be reduced with preventive therapy, thus emphasizing the importance of appropriate diagnostic and therapeutic interventions for latent tuberculosis infection (LTBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the diagnosis of LTBI in the HIV-infected patient. Treatment of LTBI in the HIV-infected host is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic testing for LTBI in the HIV-seronegative host is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1874176\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2655071\">",
"    <span class=\"h2\">",
"     What is latent tuberculosis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) infection is caused by inhalation of viable bacilli, which usually persist in an inactive state, known as latent TB infection (LTBI), or sometimes progress rapidly to active TB disease. Persons with LTBI are asymptomatic and not infectious. However, these latent TB bacilli remain viable and may &ldquo;reactivate&rdquo; years later and cause active symptomatic, and often transmissible, TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2655476\">",
"    <span class=\"h2\">",
"     HIV as a risk factor for active tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant infection with HIV is a leading risk factor for progression from LTBI to active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In nonendemic areas, the rate of progression to active TB disease is 5 to 8",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    among HIV-infected patients with LTBI, compared with a 10 percent lifetime risk in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/10\">",
"     10",
"    </a>",
"    ]. In resource-limited settings, where TB is the leading cause of death, the risk of reactivation is in the range of 10 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Hence, prevention of active TB disease is a high priority in HIV care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link&amp;anchor=H670608#H670608\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\", section on 'Risk factors for progression to active TB disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of active TB disease increases after HIV seroconversion, doubling within the first year of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/13\">",
"     13",
"    </a>",
"    ]. This observation may be due to rapid depletion of CD4+ T helper cells, which occurs in the gut-associated mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Thereafter, the risk of TB increases progressively with declining immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/10,16,17\">",
"     10,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Effect of HIV on TB'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2655078\">",
"    <span class=\"h1\">",
"     TB SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing methodologies for the identification of latent tuberculosis infection (LTBI) include the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) and the interferon-gamma release assay (IGRA).",
"   </p>",
"   <p>",
"    Both tests evaluate the host&rsquo;s cellular immune response to either non-specific (ie, TST) or MTB-specific (ie, IGRA) mycobacterial antigens. Various IGRAs are available for use, including the QuantiFERON-TB Gold In-Tube (Cellestis Limited) and the T-SPOT.TB test (Oxford Immunotec). There is no diagnostic gold standard for LTBI; thus the terms sensitivity and specificity are only estimations of test performance for either modality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/18\">",
"     18",
"    </a>",
"    ]. Detailed information about the performance of TST and IGRAs for the diagnosis of LTBI in the HIV-seronegative host is found elsewhere. The application of these diagnostic tests in the HIV-infected patient is discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15333818\">",
"    <span class=\"h1\">",
"     TUBERCULIN SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) is used to identify individuals with previous sensitization to mycobacterial antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1875364\">",
"    <span class=\"h2\">",
"     How is the test performed?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TST is an intradermal injection of tuberculin protein (ie, purified protein derivative [PPD]), which stimulates a delayed type hypersensitivity response, mediated by T-lymphocytes. The hypersensitivity response leads to induration within 48 to 72 hours. Information on dosing and the proper technique of administration is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Tuberculin skin test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1875595\">",
"    <span class=\"h2\">",
"     Interpreting the tuberculin skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients, a TST with &ge;5 mm of induration is considered reactive, while in the HIV-uninfected host, a TST with &gt;10 mm of induration is considered reactive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Tuberculin skin test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lower threshold for TST reactivity is considered positive in the HIV-infected host since HIV infection is associated with lower proliferative T-cell responses and reduced interferon-gamma production in response to mycobacterial antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, qualitative impairment of T-cell responses to mycobacterial antigens may persist despite HIV RNA suppression on antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1875782\">",
"    <span class=\"h3\">",
"     Positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with a positive TST should receive preventive therapy after active TB disease has been ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two important causes of false positive tests with the TST: nontuberculous mycobacteria infection and prior Bacillus Calmette-Guerin (BCG) vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/21\">",
"     21",
"    </a>",
"    ]. However, in HIV-infected patients, potential causes of false positive tests should not influence the decision to administer LTBI therapy because of the elevated risk of active TB disease in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1875602\">",
"    <span class=\"h3\">",
"     Negative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, clinical trials have demonstrated that HIV-infected patients with a negative TST do not obtain any clinical benefit from preventive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, preventive therapy should not be offered to the HIV-infected patient with a negative TST. However, an HIV-infected patient with recent TB exposure would still be a candidate for preventive therapy, regardless of the TST result.",
"   </p>",
"   <p>",
"    False negative TST results may occur in HIV-infected patients with advanced immunosuppression (eg, &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"     5",
"    </a>",
"    ]. A repeat TST should be considered in an HIV-infected patient when CD4 cell counts rise after initiation of potent ART.",
"   </p>",
"   <p>",
"    Other causes of a false negative TST, regardless of HIV status, include improper tuberculin handling or placement or incorrect interpretation of the test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1875867\">",
"    <span class=\"h3\">",
"     Anergy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, anergy testing with control antigens such as mumps and Candida was previously thought to help determine between true negative and false negative tuberculin tests among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The TST is negative and the control antigens are positive in an HIV-infected patient who is truly negative for latent TB infection (LTBI). In contrast, anergic patients, who are usually severely immunocompromised, have no reaction to any of these antigens. Anergy is also associated with an increased risk of overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two clinical trials in resource-rich and resource-limited settings addressed the value of preventive TB therapy among anergic HIV-infected patients compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Neither trial suggested clear clinical benefit of preventive therapy in this patient population. On the basis of these trials, and other studies demonstrating the limitations of this approach, anergy testing is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5317655\">",
"    <span class=\"h2\">",
"     Tuberculin skin testing as a predictor of TB disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a positive association between tuberculin reactivity and the risk of active TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <strong>",
"    </strong>",
"    and this",
"    <strong>",
"    </strong>",
"    enables the identification of a subset of HIV-infected patients who may attain clinical benefit from therapeutic interventions. In a 2010 meta-analysis of multiple clinical trials, preventive therapy reduced the risk of TB by 62 percent among 2378 HIV-infected patients with a positive TST; however, no clinical benefit was demonstrated among 2822 HIV-infected patients who were TST-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar observations were made in a subsequent placebo-controlled clinical trial of TB preventive therapy among 1995 HIV-infected patients in Botswana [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link&amp;anchor=H6036760#H6036760\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\", section on 'Clinical trials of latent TB treatment in HIV-infected patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5317662\">",
"    <span class=\"h3\">",
"     Effect of immunosuppression on risk of TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of active TB disease increases as the CD4 cell count declines among patients with prior TB exposure, as assessed by TST [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/31\">",
"     31",
"    </a>",
"    ]. This concept was well illustrated in an observational study of 2695 HIV-infected patients who underwent testing for LTBI in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of developing TB over 91 weeks of follow-up was strongly associated with TST reactivity in conjunction with assessment of general immunity. The incidence of TB among those who were TST reactive was 2.6",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    for those with a CD4 cell count of &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    6.5 percent",
"    <span class=\"nowrap\">",
"     /year",
"    </span>",
"    for those with a CD4 cell count from 200 to",
"    <span class=\"nowrap\">",
"     350/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    and 13.3",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    for those with a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15333885\">",
"    <span class=\"h1\">",
"     INTERFERON-GAMMA RELEASE ASSAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2655376\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-gamma release assays (IGRAs) are surrogate markers of M. tuberculosis infection and indicate a cellular immune response to M. tuberculosis specific proteins. IGRAs cannot distinguish between latent infection and active TB disease, and should not be used for diagnosis of active TB, which is a microbiological diagnosis.",
"   </p>",
"   <p>",
"    The use of IGRAs for the detection of LTBI in HIV-uninfected persons is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link&amp;anchor=H4851487#H4851487\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\", section on 'Sensitivity and specificity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594587\">",
"    <span class=\"h2\">",
"     How is the test performed?",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGRAs are performed on a single blood specimen. IGRA results may be available in 24 to 48 hours, and in contrast to TST, do not require a follow-up visit for reading of results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2655251\">",
"    <span class=\"h2\">",
"     Types of assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGRAs include the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) and the T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The QFT-GIT is an enzyme-linked immunosorbent assay that uses peptides from three TB antigens. The result is reported as quantification of interferon-gamma responses in international units per milliliter",
"      <span class=\"nowrap\">",
"       (IU/mL).",
"      </span>",
"      A patient is considered positive for M. tuberculosis infection if the antigen-specific interferon-gamma level exceeds a specific cut-off value, after subtracting the interferon-gamma value in the negative control well.",
"     </li>",
"     <li>",
"      The T-SPOT.TB is an enzyme-linked immunospot assay performed on separated and counted peripheral blood mononuclear cells. The result is reported as number of interferon-gamma producing T cells (&ldquo;spot forming&rdquo; cells). An individual is considered positive for M. tuberculosis infection if the spot counts in the TB antigen wells exceed a specific threshold relative to the control wells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196088\">",
"    <span class=\"h2\">",
"     Interpreting test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of IGRAs is more objective, while TST interpretation is affected by inter- and intra-reader variation.",
"   </p>",
"   <p>",
"    Unlike the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST), which uses risk-stratified cut-offs (with the lowest threshold of 5 mm for HIV-infected persons), neither QFT nor T-SPOT.TB uses a risk-stratified cut-off. Thus, the threshold for a positive test result is the same in all individuals tested, regardless of HIV status. Patients with a positive result should be treated for LTBI.",
"   </p>",
"   <p>",
"    However, an HIV-infected patient with recent exposure to a patient with active TB should be treated for LTBI (once active disease is ruled out), regardless of IGRA test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196211\">",
"    <span class=\"h2\">",
"     Test performance in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence on the performance of IGRAs was summarized in a systematic review of 37 studies with 5736 HIV-infected individuals living in low- and middle-income countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, test sensitivity is determined among culture-confirmed active TB cases since there are no gold standards for the diagnosis of latent TB infection (LTBI). As noted in HIV-seronegative populations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/33\">",
"       33",
"      </a>",
"      ], the pooled sensitivity of the T-SPOT.TB assay active tuberculosis (TB) was higher than for QuantiFERON-TB Fold In-Tube (72 versus 61 percent); however, the analysis was limited by the small number of culture-confirmed TB cases.",
"     </li>",
"     <li>",
"      Neither IGRA test was more sensitive than the TST in head to head comparisons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individual studies have suggested that the sensitivity of IGRAs (particularly the T-SPOT.TB assay) is less affected by HIV-related immunosuppression than the TST [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/34\">",
"     34",
"    </a>",
"    ]; however, this meta-analysis suggested that the differences between the tests were small and outcomes varied substantially across individual studies.",
"   </p>",
"   <p>",
"    Bacille Calmette-Gu&eacute;rin (BCG) is a live strain of Mycobacterium bovis developed by Calmette and Gu&eacute;rin for use as an attenuated vaccine to prevent TB and other mycobacterial infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because IGRAs are not affected by BCG vaccination status, IGRAs are useful for evaluation of LTBI in BCG-vaccinated individuals. Further, IGRAs appear to be unaffected by most infections with environmental nontuberculous mycobacteria, which can cause false-positive TSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, IGRAs generally offer higher specificity than the TST [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593685\">",
"    <span class=\"h2\">",
"     Utility of interferon-gamma release assays as predictor of active TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three longitudinal studies evaluated the ability of a positive IGRA result to predict the development of active TB disease among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, all studies were limited by small numbers of participants, few incident cases of TB, and short-term follow-up. Thus, the utility of IGRAs in predicting risk of developing active TB disease in HIV-infected patients has not been well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196786\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTING AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with evidence of latent TB infection (LTBI), by either TST or IGRA, should be treated. Of note, HIV-infected patients with well-documented TB exposure are treated for LTBI, regardless of test results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5,22,40\">",
"     5,22,40",
"    </a>",
"    ]. However, prior to treatment of LTBI, active TB disease needs to be excluded. (See",
"    <a class=\"local\" href=\"#H15333916\">",
"     'Evaluation for active TB disease prior to treatment of latent infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recommendations for testing for LTBI vary by geographic setting and TB prevalence, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196879\">",
"    <span class=\"h2\">",
"     Resource-rich settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high risk of TB disease, all newly identified HIV-infected individuals should undergo testing for LTBI, including patients living in low TB prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/41\">",
"     41",
"    </a>",
"    ]. This recommendation applies regardless of the age of the HIV-infected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"     5",
"    </a>",
"    ]. Generally speaking, the sensitivity of diagnostic testing for LTBI declines among patients with advanced immunosuppression; thus, diagnostic testing should be performed as soon as possible after HIV infection is detected, and before the onset of significant immunosuppression.",
"   </p>",
"   <p>",
"    If the LTBI test results are negative (with either test modality), but the patient has a low CD4 cell count (eg &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    diagnostic testing should be repeated after the patient has immunologically improved on potent antiretroviral therapy (ART) since immunosuppression may lead to false negative test results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4,42\">",
"     4,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persons at ongoing high risk of exposure should also be retested annually, including [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who have been incarcerated",
"     </li>",
"     <li>",
"      Those who live in congregate settings",
"     </li>",
"     <li>",
"      Active drug users",
"     </li>",
"     <li>",
"      Individuals with known history of recent TB exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196886\">",
"    <span class=\"h2\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong evidence from multiple trials that LTBI therapy confers a significant benefit among those HIV-infected patients who are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) positive, but not among those who are TST-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, testing for LTBI is important since treatment is then targeted to those most likely to obtain benefit and limits the risk of drug toxicity in those who will not. Thus, at least TST testing should be performed in all HIV-infected patients to assess which patients are candidates for treatment of LTBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link&amp;anchor=H6036760#H6036760\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\", section on 'Clinical trials of latent TB treatment in HIV-infected patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) also recommends that LTBI testing be performed on HIV-infected patients living in resource-constrained settings prior to initiation of therapy for LTBI where feasible, but does not require such testing before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2\">",
"     2",
"    </a>",
"    ]. This recommendation was made in view of the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have documented the operational difficulties of completing LTBI testing in resource-limited settings [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/43\">",
"       43",
"      </a>",
"      ]. Such obstacles have thwarted the widespread initiation of treatment of LTBI.",
"     </li>",
"     <li>",
"      Epidemiologic studies have demonstrated that LTBI therapy, administered without prior LTBI testing, has resulted in a 40 to 50 percent reduction in active TB disease among persons living in areas with very high incidence rates [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If LTBI testing is not available, all HIV-infected patients living in resource-limited settings should receive treatment for LTBI, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594442\">",
"    <span class=\"h1\">",
"     WHICH TEST SHOULD BE USED?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196291\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a 2011 meta-analysis did not find evidence to suggest that any particular methodology for LTBI testing is superior among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, given the defects in cellular immunity among HIV-infected patients, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) and interferon-gamma release assay (IGRA) methodologies would be expected to perform less well in this patient population compared with HIV-seronegative patients. Finally, comparative studies of TST with IGRA methodology in HIV-infected patients have demonstrated a significant degree of discordance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/18,45\">",
"     18,45",
"    </a>",
"    ]. Prospective comparative studies are needed to determine which test may better predict the benefit of treatment of latent TB (LTBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of testing for LTBI are generally limited by lack of an adequate reference standard for diagnosis. Thus, the only true measure of predictive value requires large studies with long-term follow-up to determine who develops active TB disease; such data continue to be limited among HIV-infected patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of testing methodology may take into account other relative advantages, as summarized below:",
"   </p>",
"   <p>",
"    Compared with IGRA, advantages of the TST include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No need for laboratories or specialized expertise.",
"     </li>",
"     <li>",
"      High quality data supporting the use of TST for clinical decision-making in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relatively inexpensive methodology and simplicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with the TST, advantages of IGRA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower false positive rates due to prior BCG vaccination or non-tuberculous mycobacteria.",
"     </li>",
"     <li>",
"      Better standardization of the assay.",
"     </li>",
"     <li>",
"      No need for a repeat patient visit to determine test results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision as to which test to use will also depend on resource and logistic considerations, as well as the country guidelines, which vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/32,47\">",
"     32,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196298\">",
"    <span class=\"h2\">",
"     Possible testing strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no clinical trial data on the combined use of TST with IGRA, or sequential testing, many algorithms in resource-rich settings have included such strategies for HIV-infected persons, to overcome the suboptimal sensitivity of both tests in immunosuppressed patients. For example, many countries (eg, Portugal, Slovakia, Netherlands, South Korea, Croatia, and United Kingdom) support an approach of simultaneous testing with both TST and IGRA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/48\">",
"     48",
"    </a>",
"    ]. Other countries (eg, Canada, Italy, Ireland, Saudi Arabia, and Spain) recommend IGRA testing only if the initial TST is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/49\">",
"     49",
"    </a>",
"    ]. Only Switzerland, France, and Bulgaria recommend IGRA as the initial test of choice.",
"   </p>",
"   <p>",
"    In the United States, the Centers for Disease Control (CDC) suggests that additional testing for LTBI be considered in the HIV-infected patient if the initial test (regardless of which method was chosen) was negative. If the second test is positive, the patient should be treated for LTBI. These recommendations can be found online at",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e\">",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986285\">",
"    <span class=\"h2\">",
"     Low and middle-income countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the WHO recommends testing for LTBI in resource-limited settings prior to treatment, where feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2\">",
"     2",
"    </a>",
"    ]. The World Health Organization (WHO) does not recommend the use of IGRAs in low- and middle-income countries for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is insufficient data and low quality evidence on the performance of IGRAs in low- and middle-income countries where TB and HIV infections are endemic.",
"     </li>",
"     <li>",
"      IGRAs are more costly and technically difficult to perform compared with the TST. Given comparable performance but increased cost, replacing TST by IGRAs as a public health intervention in resource-constrained settings is not recommended by the WHO.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15333916\">",
"    <span class=\"h1\">",
"     EVALUATION FOR ACTIVE TB DISEASE PRIOR TO TREATMENT OF LATENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected individuals who are TST-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IGRA-positive must promptly undergo a thorough medical evaluation to exclude active TB before initiating LTBI therapy. This is to minimize the risk of creating drug resistance from inadvertent monotherapy of active TB, which may be easily missed in HIV-infected persons. Clinicians need to be aware that HIV-infected patients with advanced immunosuppression can also have atypical presentation of TB disease, such as mediastinal lymphadenopathy, extrapulmonary disease, or subclinical infection with a normal chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15333923\">",
"    <span class=\"h2\">",
"     Individuals being considered for latent tuberculosis infection therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical evaluation prior to initiation of LTBI therapy varies depending on the geographic setting. The optimal approach to patient management is described below. This approach should be used wherever radiology and molecular testing modalities are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986304\">",
"    <span class=\"h3\">",
"     Resource-rich settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all high-income countries and most middle-income countries, a chest x-ray is strongly advised prior to treatment of LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/52\">",
"     52",
"    </a>",
"    ]. In the presence of any symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest x-ray abnormalities, sputum smear examinations, culture, and other appropriate molecular tests (eg, Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF,",
"    </span>",
"    Cepheid Inc, United States) should be done to rule out active TB. The Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    assay, which can simultaneously identify M. tuberculosis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance, is superior to sputum smears for the diagnosis of TB in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/53-57\">",
"     53-57",
"    </a>",
"    ] and is recommended by the World Health Organization (WHO) as the initial test in HIV-infected persons with suspected TB [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues regarding the diagnosis of active TB infection in HIV-infected patients are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1072810\">",
"    <span class=\"h3\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas where radiography, sputum spears, and molecular tests are not available, the WHO has recommended that patients be screened for symptoms (current cough, fever, weight loss, and night sweats), with initiation of LTBI therapy in the absence of sputum culture (or a chest x-ray, if radiographic facilities are not readily available) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/2\">",
"     2",
"    </a>",
"    ]. This recommendation is based on a meta-analysis of 9626 patients from 12 studies, in which the absence of these four symptoms had a negative predictive value of 98 percent (where the prevalence of active TB among HIV-infected patients was 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/52\">",
"     52",
"    </a>",
"    ]. This screening strategy has also been shown to be applicable to pregnant women as well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/58\">",
"     58",
"    </a>",
"    ]. In the setting of fever, cough, or weight loss, chest x-ray (where available) can improve the diagnosis of active TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the sensitivity of symptom screening among patients on antiretroviral therapy (ART) is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/46/12009/abstract/60\">",
"     60",
"    </a>",
"    ]. Therefore, it would be prudent to perform a sputum culture prior to initiation of LTBI therapy in settings where this is feasible.",
"   </p>",
"   <p>",
"    The evaluation of the patient with suspected TB is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594566\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TB infection is caused by inhalation of viable bacilli, which usually persist in an inactive state, known as latent TB infection (LTBI), or sometimes progress rapidly to active TB disease. Persons with LTBI are asymptomatic and not infectious. However, these latent TB bacilli remain viable and may &ldquo;reactivate&rdquo; years later and cause active symptomatic, and often transmissible, TB disease. (See",
"      <a class=\"local\" href=\"#H2655071\">",
"       'What is latent tuberculosis?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with LTBI have a significantly elevated risk of developing active TB disease, particularly those who have advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H2655476\">",
"       'HIV as a risk factor for active tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic testing modalities for LTBI include the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      and the interferon-gamma release assay. Both tests evaluate the host&rsquo;s cellular immune response to mycobacterial antigens. (See",
"      <a class=\"local\" href=\"#H2655078\">",
"       'TB screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      is an intradermal injection of tuberculin protein, which stimulates a delayed type hypersensitivity response that leads to induration within 48 to 72 hours. Among HIV-infected patients, a tuberculin skin test with &ge;5 mm of induration is considered reactive, while in the HIV uninfected host, a tuberculin skin test with &gt;10 mm of induration is considered reactive. (See",
"      <a class=\"local\" href=\"#H15333818\">",
"       'Tuberculin skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interferon-gamma release assays are performed on a single blood specimen. Test results are available in 24 to 48 hours, and in contrast to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      , do not require a follow-up visit for reading of results. Interpretation of interferon-gamma release test results is more objective than tuberculin skin testing and the threshold for a positive test result is the same in all individuals tested, regardless of HIV status. (See",
"      <a class=\"local\" href=\"#H15333885\">",
"       'Interferon-gamma release assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available evidence suggests that neither interferon-gamma release assays nor the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      have high accuracy for the prediction of active tuberculosis in HIV-infected patients with LTBI. (See",
"      <a class=\"local\" href=\"#H593685\">",
"       'Utility of interferon-gamma release assays as predictor of active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high risk of TB disease in immunocompromised patients, all newly identified HIV-infected individuals should undergo testing for LTBI. In resource-limited settings, the World Health Organization recommends that testing for LTBI be performed on HIV-infected patients prior to initiation of therapy for LTBI, where feasible. If testing for LTBI is not possible, treatment for LTBI should be administered to all HIV-positive patients. (See",
"      <a class=\"local\" href=\"#H1196786\">",
"       'Indications for testing and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since there are no data to suggest that any diagnostic modality is superior for the evaluation of LTBI in the HIV-infected host, decisions about which test to use may be influenced by accessibility, cost, and patient convenience. In some countries, both tests are utilized to overcome the problem of suboptimal test sensitivity induced by immunosuppression. (See",
"      <a class=\"local\" href=\"#H594442\">",
"       'Which test should be used?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active TB disease must be excluded in any HIV-infected patient with evidence of LTBI to minimize the risk of drug resistance secondary to inadvertent monotherapy. In all settings, ideally, a chest x-ray and history and physical examination are recommended along with microbiologic evaluation, if indicated. In resource-limited settings with limited ancillary services, a medical history alone, focused on the absence of symptoms of cough, weight loss, fevers, and night sweats, is considered adequate screening. (See",
"      <a class=\"local\" href=\"#H15333916\">",
"       'Evaluation for active TB disease prior to treatment of latent infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/1\">",
"      Lawn SD, Wood R, Wilkinson RJ. Changing concepts of \"latent tuberculosis infection\" in patients living with HIV infection. Clin Dev Immunol 2011; 2011.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for Intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings, Geneva, 2011.",
"    </li>",
"    <li>",
"     file://www.who.int/tb/publications/global_report/2009/en/index.html (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/4\">",
"      Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; :CD000171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/5\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/tb/3is_mreport/en/index.html (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/8\">",
"      van der Sande MA, Schim van der Loeff MF, Bennett RC, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004; 18:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/9\">",
"      Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/10\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2010. World Health Organization, Geneva 2011 (WHO/HTM/TB/2010.362).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/12\">",
"      Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/13\">",
"      Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/14\">",
"      Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/15\">",
"      Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/16\">",
"      Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/17\">",
"      Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/18\">",
"      Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/19\">",
"      Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/20\">",
"      Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/21\">",
"      Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/22\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"    <li>",
"     Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield's Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), Informa Healthcare USA, New York 2006. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/24\">",
"      Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 58:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/25\">",
"      Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/26\">",
"      Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/27\">",
"      Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1996; 153:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/28\">",
"      Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/29\">",
"      Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000; 4:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/30\">",
"      Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/31\">",
"      Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/32\">",
"      Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/33\">",
"      Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/34\">",
"      Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/35\">",
"      Adams LV, Waddell RD, Von Reyn CF. T-SPOT.TB Test(R) results in adults with Mycobacterium avium complex pulmonary disease. Scand J Infect Dis 2008; 40:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/36\">",
"      Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/37\">",
"      Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/38\">",
"      Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/39\">",
"      Elliott JH, Vohith K, Saramony S, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200:1736.",
"     </a>",
"    </li>",
"    <li>",
"     Tuberculosis Prevention and Control, Public Health Agency of Canada, the Canadian Lung Association. Canadian Lung Association, 6th ed, Long RL, Ellis E.  (Eds), Public Health Agency of Canada, Toronto 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/41\">",
"      Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/42\">",
"      Fisk TL, Hon HM, Lennox JL, et al. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS 2003; 17:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/43\">",
"      Aisu T, Raviglione MC, van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/44\">",
"      Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/45\">",
"      Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/46\">",
"      Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-&gamma; release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/47\">",
"      Denkinger CM, Dheda K, Pai M. Guidelines on interferon-&gamma; release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17:806.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection&mdash;2010 Update. file://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10pdf/36-acs-5.pdf (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. The use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. Geneva, WHO, 2011. file://whqlibdoc.who.int/publications/2011/9789241502672_eng.pdf (Accessed on February 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/51\">",
"      Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/52\">",
"      Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8:e1000391.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, WHO, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/54\">",
"      Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/55\">",
"      Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8:e1001061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/56\">",
"      Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/57\">",
"      Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/58\">",
"      Gupta A, Chandrasekhar A, Gupte N, et al. Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis. Clin Infect Dis 2011; 53:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/59\">",
"      Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/46/12009/abstract/60\">",
"      Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 2012; 55:1698.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16662 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-201.248.109.99-36184B143A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12009=[""].join("\n");
var outline_f11_46_12009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H594566\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1873885\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1874176\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2655071\">",
"      What is latent tuberculosis?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2655476\">",
"      HIV as a risk factor for active tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2655078\">",
"      TB SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15333818\">",
"      TUBERCULIN SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1875364\">",
"      How is the test performed?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1875595\">",
"      Interpreting the tuberculin skin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1875782\">",
"      - Positive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1875602\">",
"      - Negative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1875867\">",
"      - Anergy testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5317655\">",
"      Tuberculin skin testing as a predictor of TB disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5317662\">",
"      - Effect of immunosuppression on risk of TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15333885\">",
"      INTERFERON-GAMMA RELEASE ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2655376\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594587\">",
"      How is the test performed?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2655251\">",
"      Types of assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196088\">",
"      Interpreting test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196211\">",
"      Test performance in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H593685\">",
"      Utility of interferon-gamma release assays as predictor of active TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1196786\">",
"      INDICATIONS FOR TESTING AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196879\">",
"      Resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196886\">",
"      Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H594442\">",
"      WHICH TEST SHOULD BE USED?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196291\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196298\">",
"      Possible testing strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H986285\">",
"      Low and middle-income countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15333916\">",
"      EVALUATION FOR ACTIVE TB DISEASE PRIOR TO TREATMENT OF LATENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15333923\">",
"      Individuals being considered for latent tuberculosis infection therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H986304\">",
"      - Resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1072810\">",
"      - Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H594566\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_46_12010="Basic case 12 with answer";
var content_f11_46_12010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in acute pericarditis showing diffuse upsloping ST segment elevations seen best here in leads II, III, aVF, and V3 to V6. There is also subtle PR segment deviation (positive in aVR, negative in most other leads). ST segment elevation is due to a ventricular current of injury associated with epicardial inflammation; similarly, the PR segment changes are due to an atrial current of injury which, in pericarditis, typically displaces the PR segment upward in lead aVR and downward in most other leads.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12010=[""].join("\n");
var outline_f11_46_12010=null;
var title_f11_46_12011="Neuroendocr tumors";
var content_f11_46_12011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult neuroendocrine tumors with known primary sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indolent biology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aggressive biology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Well differentiated neuroendocrine tumor (carcinoid, atypical carcinoid, many primary sites)",
"        </p>",
"        <p>",
"         Medullary carcinoma of the&nbsp;thyroid",
"        </p>",
"        <p>",
"         Well differentiated pancreatic neuroendocrine tumor (islet cell tumor)",
"        </p>",
"        <p>",
"         Paraganglioma",
"        </p>",
"        <p>",
"         Pheochromocytoma",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Poorly differentiated&nbsp;neuroendocrine carcinoma (many primary sites)",
"        </p>",
"        <p>",
"         Extrapulmonary small cell carcinoma (many primary sites)",
"        </p>",
"        <p>",
"         Merkel cell tumor of the skin&nbsp;skin",
"        </p>",
"        <p>",
"         Neuroblastoma, adrenal",
"        </p>",
"        <p>",
"         Small cell lung cancer",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with modifications from: Greco FA, Hainsworth JD. Cancer of Unknown Primary site. In: Cancer: Principles and Practice of Oncology 8th edition, DeVita VT, Lawrence TS, Rosenberg SA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12011=[""].join("\n");
var outline_f11_46_12011=null;
var title_f11_46_12012="Diagnostic criteria PCOS";
var content_f11_46_12012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed diagnostic criteria for polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        NIH consensus criteria 1990",
"        <sup>",
"         [1]",
"        </sup>",
"        <br/>",
"        (All required)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rotterdam criteria 2003*",
"        <sup>",
"         [2]",
"        </sup>",
"        <br/>",
"        (Two out of three required)",
"       </td>",
"       <td class=\"subtitle1\">",
"        AES definition 2008",
"        <sup>",
"         [3]",
"        </sup>",
"        <br/>",
"        (All required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menstrual irregularity due to oligo- or anovulation",
"       </td>",
"       <td>",
"        Oligo- or anovulation",
"       </td>",
"       <td>",
"        Clinical and/or biochemical signs of hyperandrogenism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical and/or biochemical signs&nbsp;of hyperandrogenism",
"       </td>",
"       <td>",
"        Clinical and/or biochemical signs of hyperandrogenism",
"       </td>",
"       <td>",
"        Ovarian dysfunction &ndash; oligo-anovulation and/or polycystic ovaries on ultrasound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exclusion of other disorders: NCCAH, androgen-secreting tumors",
"       </td>",
"       <td>",
"        Polycystic ovaries (by ultrasound)",
"       </td>",
"       <td>",
"        Exclusion of other androgen excess or ovulatory disorders",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NIH: National Institutes of Health; AES: Androgen Excess Society; NCCAH: nonclassic congenital adrenal hyperplasia; PCOS: polycystic ovary syndrome.",
"     <br/>",
"     * Rotterdam criteria based upon a 2003 concensus meeting held in Rotterdam (European Society of Human Reproduction and Embryology/American Society of Reproductive Medicine consensus workshop group).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Dunaif A, Givens JR, Haseltine FP, Merriam GE (Eds), Blackwell Scientific Inc., Boston 1992. p.377.",
"      </li>",
"      <li>",
"       Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.",
"      </li>",
"      <li>",
"       Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12012=[""].join("\n");
var outline_f11_46_12012=null;
var title_f11_46_12013="NCHS vs WHO growth curves";
var content_f11_46_12013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of National Center for Health Statistics and World Health Organization growth charts for children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Year published",
"       </td>",
"       <td class=\"subtitle1\">",
"        NCHS/CDC",
"       </td>",
"       <td class=\"subtitle1\">",
"        WHO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        2000",
"       </td>",
"       <td class=\"subtitle2\">",
"        2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Population(s) from which curves were derived",
"       </td>",
"       <td>",
"        General US population (data from the National Health and Nutrition Survey between 1970s and 1990s); includes infants and children from a variety of socioeconomic and ethnic groups",
"       </td>",
"       <td>",
"        Multicentre Growth Reference study (Brazil, Ghana, India, Norway, Oman, United States); population chosen to reflect growth under ideal conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age groups",
"       </td>",
"       <td>",
"        <p>",
"         0 to 36 months (cross-sectional data; includes both breastfed and formula-fed infants)",
"        </p>",
"        <p>",
"         2 to 20 years (cross-sectional data)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0 to 2 years (longitudinal data); infants were exclusively/predominantly breastfed for 4 to 6 months and continued to breastfeed until at least 12 months",
"        </p>",
"        <p>",
"         2 to 5 years (cross-sectional data)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Estimated prevalence of overweight in US children*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 23 months",
"       </td>",
"       <td>",
"        9.6 percent",
"       </td>",
"       <td>",
"        7.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24 to 59 months",
"       </td>",
"       <td>",
"        9.6 percent",
"       </td>",
"       <td>",
"        8.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Estimated prevalence of underweight in US children*&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Weight-for-age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        0 to 23 months",
"       </td>",
"       <td>",
"        6.8 percent",
"       </td>",
"       <td>",
"        2.0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        24 to 59 months",
"       </td>",
"       <td>",
"        3.8 percent",
"       </td>",
"       <td>",
"        0.8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Weight-for-height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        0 to 23 months",
"       </td>",
"       <td>",
"        4.0 percent",
"       </td>",
"       <td>",
"        0.8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        24 to 59 months",
"       </td>",
"       <td>",
"        3.0 percent",
"       </td>",
"       <td>",
"        0.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Estimated prevalence of shortness in US children*&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 23 months",
"       </td>",
"       <td>",
"        4.9 percent",
"       </td>",
"       <td>",
"        5.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24 to 59 months",
"       </td>",
"       <td>",
"        2.9 percent",
"       </td>",
"       <td>",
"        3.1 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NCHS: National Center for Health Statistics; CDC: Centers for Disease Control; WHO: World Health Organization.",
"     <br>",
"      * Using data from the National Health and Nutrition Examination Survey (1999-2004).",
"      <br>",
"       &bull; On the NCHS curves, overweight is defined by weight-for-height &gt;95th percentile for children 0 to 23 months and BMI &gt;95th percentile for children 24 to 59 months. On the WHO curves,&nbsp;overweight is defined&nbsp;by weight-for-height &gt;97.7th percentile for children 0 to 23 months and BMI &gt;97.7th percentile for children 24 to 59 months.",
"       <br>",
"        &Delta; On the NCHS curves, underweight is defined by weight-for-age or weight-for-height &lt;5th percentile. On the WHO curves, underweight is defined&nbsp;by weight-for-age or weight-for-height &lt;2.3rd percentile.",
"        <br>",
"         &loz; On the NCHS curve, shortness defined by height-for-age &lt;5th percentile. On the WHO curve, shortness is defined&nbsp;by height-for-age&nbsp;&lt;2.3rd percentile.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data for prevalence estimates from: Mei Z, Ogden CL, Flegal KM, Grummer-Strawn LM. Comparison of the prevalence of shortness, underweight, and overweight among US children aged 0 to 59 months by using the CDC 2000 and the WHO 2006 growth charts. J Pediatr 2008; 153:622.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12013=[""].join("\n");
var outline_f11_46_12013=null;
var title_f11_46_12014="Monoclonal gammopathies disease definitions";
var content_f11_46_12014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease definitions for the monoclonal gammopathies: MGUS and related disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of monoclonal gammopathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Premalignancy with low risk of progression (1 to 2 percent per year)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Premalignancy with high risk of progression (10 percent per year)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         IgG and IgA (non-IgM)",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Non-IgM MGUS",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Serum monoclonal protein &lt;3 g/dL",
"         </li>",
"         <li>",
"          Clonal BM plasma cells &lt;10 percent",
"         </li>",
"         <li>",
"          Absence of end-organ damage such as CRAB that can be attributed to the PCPD",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Smoldering MM",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Both criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Serum monoclonal protein (IgG or IgA) &ge;3 g/dL and/or clonal BM plasma cells &ge;10 percent",
"         </li>",
"         <li>",
"          Absence of end-organ damage such as CRAB that can be attributed to a PCPD",
"         </li>",
"        </ol>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          MM",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met except as noted:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Clonal BM plasma cells &ge;10 percent",
"         </li>",
"         <li>",
"          Presence of serum and/or urinary monoclonal protein (except in patients with true nonsecretory MM)",
"         </li>",
"         <li>",
"          Evidence of end-organ damage that can be attributed to the underlying PCPD, specifically one or more of the following:",
"         </li>",
"        </ol>",
"        <ul>",
"         <li>",
"          Hypercalcemia: serum calcium &ge;11.5 mg/dL",
"         </li>",
"         <li>",
"          Renal insufficiency: serum creatinine &gt;2 mg/dL or estimated creatinine clearance &lt;40 mL/min",
"         </li>",
"         <li>",
"          Anemia: normochromic, normocytic with hemoglobin &gt;2 g/dL below lower limit of normal or hemoglobin &lt;10 g/dL",
"         </li>",
"         <li>",
"          Bone lesions: lytic lesions or severe osteopenia attributed to a PCPD or pathologic fractures",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         IgM",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          IgM MGUS",
"         </strong>",
"         &Delta;",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Serum monoclonal protein &lt;3 g/dL",
"         </li>",
"         <li>",
"          Clonal BM lymphoplasmacytic cells &lt;10 percent",
"         </li>",
"         <li>",
"          Absence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Smoldering WM",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Both criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Serum IgM monoclonal protein &ge;3 g/dL and/or BM lymphoplasmacytic infiltration &ge;10 percent",
"         </li>",
"         <li>",
"          No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          WM",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          IgM monoclonal gammopathy (regardless of size of M protein)",
"         </li>",
"         <li>",
"          &ge;10 percent BM lymphoplasmacytic infiltration (usual intertrabecular) by small lymphocytes that exhibit plasmacytoid or plasma cell differentiation and a typical immunophenotype (eg, surface IgM",
"          <sup>",
"           +",
"          </sup>",
"          , CD5",
"          <sup>",
"           &plusmn;",
"          </sup>",
"          , CD10",
"          <sup>",
"           -",
"          </sup>",
"          , CD19",
"          <sup>",
"           +",
"          </sup>",
"          , CD20",
"          <sup>",
"           +",
"          </sup>",
"          , CD23",
"          <sup>",
"           -",
"          </sup>",
"          ) that satisfactorily excludes other lymphoproliferative disorders including chronic lymphocytic leukemia and mantle cell lymphoma",
"         </li>",
"         <li>",
"          Evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          IgM myeloma",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Symptomatic monoclonal PCPD characterized by a serum IgM monoclonal protein regardless of size",
"         </li>",
"         <li>",
"          Presence of &ge;10 percent plasma cells on BM biopsy",
"         </li>",
"         <li>",
"          Presence of lytic bone lesions related to the underlying plasma cell disorder and/or translocation t(11:14) on FISH",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Light chain",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Light chain MGUS",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Abnormal FLC ratio (&lt;0.26 or &gt;1.65)",
"         </li>",
"         <li>",
"          Increased level of the appropriate involved light chain (increased &kappa; FLC in patients with ratio &gt;1.65 and increased &lambda; FLC in patients with ratio &lt;0.26)",
"         </li>",
"         <li>",
"          No immunoglobulin heavy chain expression on immunofixation",
"         </li>",
"         <li>",
"          Clonal BM plasma cells &lt;10 percent",
"         </li>",
"         <li>",
"          Absence of end-organ damage such as CRAB that can be attributed to the PCPD",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Idiopathic Bence Jones proteinuria",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          All criteria must be met:",
"         </em>",
"        </p>",
"        <ol>",
"         <li>",
"          Urinary monoclonal protein on urine protein electrophoresis &ge;500 mg/24 h and/or clonal BM plasma cells &ge;10 percent",
"         </li>",
"         <li>",
"          No immunoglobulin heavy chain expression on immunofixation",
"         </li>",
"         <li>",
"          Absence of end-organ damage such as CRAB that can be attributed to the PCPD",
"         </li>",
"        </ol>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Light chain MM",
"         </strong>",
"         &Delta;",
"        </p>",
"        <p>",
"         Same as MM except no evidence of immunoglobulin heavy chain expression on immunofixation",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BM: bone marrow; CRAB: hyper",
"     <strong>",
"      c",
"     </strong>",
"     alcemia,",
"     <strong>",
"      r",
"     </strong>",
"     enal insufficiency,",
"     <strong>",
"      a",
"     </strong>",
"     nemia, and",
"     <strong>",
"      b",
"     </strong>",
"     one lesions; FISH: fluorescent in situ hybridization; FLC: free light chain; MGUS: monoclonal gammopathy of undetermined significance; MM: multiple myeloma; PCPD: plasma cell proliferative disorder; WM: Waldenstr&ouml;m macroglobulinemia.",
"     <br>",
"      * Occasionally, patients with IgD and IgE monoclonal gammopathies have been described and will be considered part of this category as well.",
"      <br>",
"       &Delta; Note that conventionally IgM MGUS is considered a subtype of MGUS, and similarly light chain MM is considered a subtype of MM. Unless specifically distinguished, when the terms MGUS and MM are used in general, they include IgM MGUS and light chain MM, respectively.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85:945. Copyright &copy; 2010 Quadrant HealthCom, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12014=[""].join("\n");
var outline_f11_46_12014=null;
var title_f11_46_12015="Retropharyngeal abscess CT";
var content_f11_46_12015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retro- and parapharyngeal abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The computed tomography of the neck&nbsp;shows retro- and parapharyngeal abscess (A, B)&nbsp;as indicated by&nbsp;a low-density core, soft-tissue swelling, obliterated fat planes, mass effect, and rim enhancement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_46_12015=[""].join("\n");
var outline_f11_46_12015=null;
